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Abstract 
In this study, a range of single-ligand and heteroleptic copper(II) Schiff base chelates were 
synthesised as potential chemotherapeutic agents. The copper(II) chelates are anticipated to 
exert their cytotoxicity via DNA cleavage (through the production of hydroxyl radicals) and 
DNA binding. Three single-ligand copper(II) chelates were successfully synthesised and 
characterised. Two of these had N,N’,N’’ donor atom sets: [Cu(L)(Cl)2] and [Cu(L2)(Cl)2], which 
were synthesised by the reactions of pyridine-2-carbaldehyde with picolylamine and  
8-aminoquinoline, respectively. The third Schiff base had N,N’,O donor atoms and was 
synthesised by the reaction of salicylaldehyde and 8-aminoquinoline. Reaction of the 
respective ligands with CuCl2 yielded the desired chelates. [Cu(L1)(Cl)] was then further 
reacted with three co-ligands: 2,2’-bipyridyl, 1,10-phenanthroline and 1,10-phenanthroline-5-
amine to afford three heteroleptic chelates. The ligands and chelates have been characterised 
by mass spectrometry, CHN analysis as well as NMR (where possible), IR and UV/vis 
spectroscopy. DNA binding affinities of the copper(II) chelates were measured using 
fluorescence competitive binding assays. The binding affinities of the complexes ranged from 
1.75 × 105 – 8.65 × 105 M-1. [Cu(L1)(Cl)] was the strongest binder, while [Cu(L)(Cl2)] was the 
weakest. 
The solid state structures of two single-ligand and the three heteroleptic chelates were 
elucidated. The copper(II) chelates all exhibited a square pyramidal coordination geometry. 
Measurements of the angle subtended by the ligand planes showed interesting variations of 
ring bending as well as angle deviations in the three heteroleptic complexes. DFT simulations 
were used to run geometry optimisations on all copper(II) chelates at the B3LYP/6-311G(d,p) 
level of theory to investigate the influence of intermolecular forces on the geometry of the 
chelates. RMSDs for both the single-ligand and heteroleptic chelates were low indicating good 
correlation between the gas phase and solid state structures. The similarity of the structures 
suggests that an appropriate level of theory was applied in the simulations. The key difference 
in the structures was the angle subtended by the primary and co-ligands in the absence of 
packing constraints. The DFT-optimised structures tended towards a trigonal bipyramidal 
geometry as opposed to a square pyramidal geometry. 
Hydroxyl radical studies showed that all the copper(II) chelates have the ability to produce 
hydroxyl radicals in situ in the presence of ascorbic acid and hydrogen peroxide. The in vitro 
cytotoxicity of all six copper(II) chelates were assessed against a panel of four human cell lines 
of which three were cancer cell lines: TK-10, U937 and MT-4. The forth cell line was a normal 
human cell line and was used as a control (HEK293). The most active copper(II) chelate was 
[Cu(L)(Cl)2] with the highest mean activity (IC50 = 2.19 µM) against the three cancer cell lines. 
[Cu(L)(Cl)2] was also screened against HEK293 and showed lower cytotoxicity (IC50 = 3.18).  The 
cytotoxicity in general did not correlate with the DNA binding affinities, suggesting that the 
mechanism of action may be more complicated than simply inhibiting cell replication through 
DNA binding. The catalytic production of reactive oxygen species is therefore likely a key 
aspect in the mechanism of action. 
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Chapter 1 | Introduction 
1.1 Preface 
Cancer is a genetic disease which has plagued humankind for generations. It has become a 
global health threat, affecting individuals all around the world, regardless of socioeconomic 
status. Cancer remains the second leading cause of death in developing countries and the 
number one cause of death in developed countries.1 Statistics from the National Cancer 
Institute (USA) show that the most prevalent cancers in 2016 are of the breast, lung and 
bronchus, prostate and colon.1 In 2016, an estimated 1,685,210 new cases of cancer will be 
diagnosed in the United States alone and 595,690 people will die from this disease. The 
number of new cancer cases worldwide is expected to rise to 22 million within the next two 
decades.1 
These alarming statistics have fuelled cancer research for the past four decades. However, 
drawbacks such as the lack of selectivity and toxic side effects of current chemotherapeutics 
have prompted researchers to continue development of new and improved drugs which are 
aimed to be more selective with reduce side effects.2 
Metals play various roles within living systems and medicinal inorganic chemistry has been 
practiced for millennia. The first recorded medicinal use of copper was found in an ancient 
Egyptian medical text, written between 2600 and 2200 B.C., which records the use of copper 
to sterilise chest wounds and drinking water.3 Copper has since been shown to have numerous 
antibacterial and antifungal properties and its cytotoxicity when used as a base for 
chemotherapeutics has shown promising results.4 An additional advantage of copper derived 
chemotherapeutics is that they are one of few classes of compounds with the potential for 
both diagnosis and treatment of cancerous lesions.4 
This study focuses on the synthesis of single-ligand and heteroleptic Schiff base copper(II) 
chelates which are anticipated to exert their cytotoxicity by two mechanisms: Firstly, by 
intercalating between the base pairs of the DNA helix, hindering DNA replication. Secondly, 
copper(II), being a redox active metal, can catalyse the production of hydroxyl radicals which 
will cleave DNA inducing tumour cell apoptosis. The significance of selecting Schiff bases, 
heteroleptic chelate systems and copper(II) will be outlined in this chapter. 
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1.2 Transition Metals in Medicine 
It is a well-established fact that most drugs in the pharmaceutical sector are “organic” in 
nature. However, in recent years other elements in the Periodic Table, metals in particular, 
have been shown to have important medicinal properties with some being essential for 
normal biological function in humans.5 The discipline of inorganic medicinal chemistry was 
born after the serendipitous discovery of the platinum-based anticancer drug cisplatin, which 
remains one of the best-selling anticancer drugs today.2 Cisplatin and its derivatives, 
oxaliplatin and carboplatin, have been very effective in treating cancer, but show activity 
towards only a limited number of tumours. Further drawbacks of using platinum-based drugs 
are that secondary tumours often show drug resistance during treatment and they induce 
intense side effects.2 
These findings led to the progression of inorganic medicinal chemistry away from solely 
platinum-based drugs. Current research in medicinal inorganic chemistry is directed towards 
two goals. The first is the synthesis of new anticancer drugs with the potential to overcome 
the issues of drug resistance. The second focus is to develop metal-based drugs with higher 
selectivity towards neoplastic tissue over healthy tissue leading to a significant reduction in 
the side effects of treatment.2 Clinical and preclinical research have shown that the 
development of new cytostatic metal agents with novel modes of action can be achieved.6 
The application of metals in medicinal chemistry may at first seem an odd choice. However, 
provided the metal ions can be stabilised in the reducing cellular environment of mammalian 
cells, they can serve as an ideal scaffold around which ligands baring cell targeting groups can 
be attached in a precise three-dimensional arrangement. Gold, iron and cobalt complexes 
have already shown encouraging results in preclinical studies while gallium, titanium and 
ruthenium metal complexes have passed into phase I and phase II clinical trials.6 These metal-
based drugs and drug candidates are discussed below. 
Gold(I)-based compounds, particularly cyanide complexes, were used in the treatment of 
human and bovine tuberculosis (TB) for several years in the early 20th century.6 Auranofin, a 
gold(I) phosphine complex is one of the compounds used for the treatment of rheumatoid 
arthritis. However, in the early 1980s reports showed that Auranofin and other gold(I) 
phosphine complexes could inhibit the growth of tumour cells in vitro. Auranofin did not 
interact directly with DNA like other gold complexes, but inhibited synthesis of RNA, DNA and 
protein at cytotoxic concentrations. Exposing cells to Auranofin also resulted in morphological 
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changes such as cell rounding and surface membrane changes.6 Figure 1.2.1 shows the 






Figure 1.2.1: Structure of the gold(I) anti-arthritic and anti-tumour agent Auranofin.3 
Gold(III) complexes show electronic and structural similarities to cisplatin rendering them 
ideal candidates in the search for potential anticancer agents. A drawback of gold(III) 
complexes is that they exhibit low stability under physiological conditions which has slowed 
the development of these drugs.7 A wide range of gold(III) complexes with various ligands 
have in recent years been synthesised and biochemically investigated. Most of these 
complexes contain Au-N bonds for example, [Au(phen)Cl2]Cl, [Au(terpy)Cl]Cl2 and 
[AuCl(dien)]Cl2 (depicted in Figure 1.2.2). These complexes all showed good stability in 
physiological-like environments. In addition, all three compounds showed promising cytotoxic 
activities towards human ovarian cancer cells (A2780).7  
It is also noted that this class of complexes could overcome the issue of drug resistance in 
cisplatin-resistant A2780 cells.7 In the presence of thiosulfate or ascorbate, the compounds 
[Au(phen)Cl2]Cl and [Au(terpy)Cl]Cl2 were readily reduced indicating the release of their toxic 






Figure 1.2.2: Cytotoxic gold(III) complexes with N-donor ligands (a) [Au(phen)Cl2]Cl, (b) [Au(terpy)Cl]Cl2 and (c) 
[AuCl(dien)]Cl2. 
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Budotitane and titanocene dichloride, Figure 1.2.3, are titanium complexes which have both 
passed into clinical trials. Preclinical trials of these complexes have shown cytotoxic activity 
against a wide variety of cancerous tissues. Budotitane was studied in a clinical phase I trial 
which showed no objective tumour response.6 Titanocene dichloride delivered encouraging 
results in phase I trials and was moved to phase II trials. Once in phase II trials, patients with 
metastatic renal-cell carcinoma showed no response. The hydrolytic instability under 
physiological conditions and the poor solubility in aqueous media of titanocenium compounds 








Figure 1.2.3: Structures of cytotoxic titanium complexes (a) budotitane and (b) titanocene dichloride. 
Reports indicating the potential anti-cancer properties of ruthenium complexes surfaced as 
early as the 1970s, thus leading to increased efforts in this field. Numerous potential 
chemotherapeutics have since emerged, such as the octahedral ruthenium(III) complexes 
NAMI-A and KP1019, shown in Figure 1.2.4, which have entered clinical trials.6  KP1019 
showed cell growth inhibitory effects on cultured cancer cells and is efficiently taken up by 






Figure 1.2.4: Ruthenium complexes NAMI-A and KP1019, which have entered clinical trials for the treatment of various 
malignant tumours.3 
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The examples above are just a small extract of the vast library of metal chelates which have 
shown potential in drug research. The inclusion of metal ions in the next generation of 
chemotherapeutics will hopefully adjust mechanisms of action, helping to overcome the 
issues associated with current therapies. Targeted drug delivery with correspondingly reduced 
side effects holds the key to more effective and selective drug administration; this can be 
achieved with metal-based chemotherapeutics.8  
1.3 Copper Chemistry 
The applications of copper in medicinal chemistry date back centuries when ancient Egyptians, 
Romans, Greeks and Aztecs reported the application of copper for the treatment of various 
ailments.9 Copper is an essential element for plants, animals and humans and for this reason 
it is believed that copper-based medicinal compounds could be less toxic to healthy tissue 
than exogenous metals such as platinum.9 
The aqueous coordination chemistry of copper is limited to its three accessible oxidation 
states (I-III). Copper(I) has a diamagnetic d10 configuration and forms complexes without any 
crystal field stabilisation energy. Copper(II) is a d9 metal of borderline softness, which favours 
a wide range of coordination geometries. Copper(III) is uncommon and is only stable with the 
use of strong π-donor ligands.10 
The d9 electronic configuration of copper(II) makes it subject to Jahn-Teller distortion when 
placed in an environment of cubic symmetry. The Jahn-Teller effect which describes the 
geometrical distortion of ions and molecules is associated with certain electronic 
configurations. The Jahn–Teller theorem states that any non-linear molecule with a 
spatially degenerate electronic ground state will undergo a geometrical distortion that 
removes that degeneracy, because the distortion lowers the overall energy of the species. The 
effect is most commonly encountered in octahedral complexes of the transition metals.11 
Copper(II) favours coordination to amines, imines, and bidentate ligands to form distorted 
square-planar, square-pyramidal, trigonal-pyramidal, and distorted octahedral geometries. 
When hexa-coordinate, the typical distortion is an elongation along one four-fold axis i.e. four 
normal bonds lie in a square-planar configuration (equatorial positions) and two longer or 
shorter bonds occur above and below the plane (axial positions). This distortion is a result of 
the Jahn-Teller effect. 12   
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1.3.1 Copper-Based Antimicrobials 
Research has shown copper, particularly copper(II), to have both antimicrobial and anticancer 
properties.13 Antimicrobial agents have the ability to kill or inactivate microbes, such as 
bacteria, fungi and viruses. Numerous scientific studies have shown that copper has a reliable 
antimicrobial activity against some toxic bacteria, viruses and fungi including Escherichia 
coli, Bacillus subtilis and Staphylococcus aureus to name a few.4 Antibiotic resistance is also 
on the increase and research to develop new, more efficient drugs to control pathogenic 
organisms is an ongoing process. 
There are various mechanisms through which copper exerts its activity as an antimicrobial 
agent. These mechanisms include: 
 The alteration of the three-dimensional structure of proteins  by coordination to 
various amino acids in the proteins which leads to the inactivation of viruses and 
bacteria.14 
 The formation of highly reactive hydroxyl radicals by copper(II) complexes which 
inactivate viruses by impairing the viral proteins.15 
 Copper readily binds to the sulfur, carboxylate-containing and amino groups of 
proteins disrupting the structure and functions of enzymes.16 
 Copper interacts with lipids resulting in peroxidation and the formation of holes in the 
cell membrane resulting in leakage of essential solutes.17 
 The cellular metabolism in Escherichia coli cells is impaired by damage to the 
respiratory chain caused by copper.18 
In a study by Mezey et al. the antimicrobial potential of a series of copper(II) complexes was 
investigated along with the free ligand, pyridoxal isonicotinoyl hydrazone (HL), which acts as 
a control, against a spectrum of Gram-positive and Gram-negative bacteria. The antimicrobial 
activity of the solvents (pyridine and dimethylsulfoxide), HL and the newly synthesised 
copper(II) hydrazone compounds were tested against Escherichia coli W3110, Pseudomonas 
aeruginosa ATCC 9027 (Gram-positive), Staphylococcus aureus ATTC 6538 (Gram-negative) 
and Bacillus cereus ATCC 14579 bacterial strains.19 The study was successful in confirming a 
significantly higher antimicrobial activity for the copper(II) complexes compared to the free 
ligand. The increased antimicrobial activity of the copper(II) hydrazone complexes is due to 
direct contact of the copper(II) complexes with the pathogenic bacteria. The chelates cause 
cell damage by membrane rupture resulting in loss of cytoplasmic content and loss of 
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membrane potential leading to cell death.19 Figure 1.3.1 illustrates the solid state structure of 








Figure 1.3.1: The ligand pyridoxal isonicotinoyl hydrazone (HL) and proposed structure of the copper(II) antimicrobial 
complex.19 
 
1.3.2 Copper Toxicity 
The toxicity of copper(II) originates from its ability to produce reactive oxygen species (ROS), 
as shown in Figure 1.3.2 , in vivo. These are chemically reactive molecules containing oxygen. 
They also have the ability to displace other metal ions, peroxidise lipids and directly cleave 
DNA and RNA. In many types of cancers such as prostate, breast, colon, lung and brain cancer 
there have been reports of elevated levels of copper.20 
 
There are at least two possible mechanisms in which the copper(II) complexes can generate 
hydroxyl radicals (an example of a ROS), namely the Fenton and Harber-Weiss mechanisms. 
In the Fenton mechanism Copper(II) is reduced to Copper(I), usually by ascorbate, which is a 
naturally occurring thiol (HS-R-S-). The copper(I) then reacts with hydrogen peroxide via a 
redox reaction to produce hydroxyl radicals.20 The following reaction scheme illustrates the 
hydroxyl radical formation: 
HS-R-S- + Cu2+ → HS-R-S· + Cu+ 
HS-R-S· + O2 → S-S-R + H+ + O2-. 
2O2-. + 2H+ → H2O2 + O2 
Cu+ + H2O2 → OH· + OH- + Cu2+ 
OH· + DNA → Fragments 
Scheme 1: The reaction equations for the formation of hydroxyl radicals for DNA degradation catalysed by copper(II). 
Page | 8  
 
In the Haber-Weiss mechanism copper(I) reacts with singlet dioxygen to form copper(II) and 
a superoxide anion which further reacts with hydrogen peroxide to form hydroxyl radicals.20 
Hydrogen peroxide is generated in living organisms due to the existence of certain enzymes. 
A copper(II)/(I) redox process will lead to the formation of the superoxide ion from dioxygen. 
The superoxide can then form the dioxygen and hydrogen peroxide.20 
The following pathway in Figure 1.3.2 illustrates the sequential events for DNA cleavage 
(which is the key attribute of copper(II) chemistry which renders the complexes cytotoxic) 
performed by the copper chelates in the presence of ascorbate (2H2asc). Ascorbate is one of 






Figure 1.3.2: Formation of reactive oxygen species by copper(II) complexes in the presence of ascorbate (H2asc) leading to 
DNA cleavage and tumour cell apoptosis.21 
 
The highly reactive hydroxyl radical is able to interact with any biological molecule by taking 
the hydrogen from an amino bearing carbon to form a carbon-centred protein radical or from 
an unsaturated fatty acid to form a lipid radical. The electron deficient hydroxyl radicals can 
induce both single and double-stranded cleavage of the electron-rich DNA helix. The latter is 
particularly difficult for cellular regulatory systems to repair and is therefore an efficient 
method to control tumour cell growth.21 
 
Previous work in the Akerman Research group has shown that copper(II) chelates can be 
effective chemotherapeutic agents. Shown below in Figure 1.3.3 are the structures of some 
of the chelates that the group has previously synthesised and screened against human tumour 
cell lines. 











Figure 1.3.3: Previously synthesised Cu(II)-based chemotherapeutic agents. 
These compounds have proven to be effective against a range of human tumour cell lines as 
shown in Table 1.3.1. It is interesting to note that the free ligands exhibited significantly less 
cytotoxicity towards the same tumour cell lines (IC50 > 100 μM). This difference in activity 
illustrates the importance of the copper(II) ion in the mechanism of action. The increased 
cytotoxicity was attributed to the copper(II) chelate’s ability to catalyse the production of 
hydroxyl radicals in vitro. These radicals induce single and double-stranded DNA cleavage 
which would induce cell apoptosis. The ability of the above chelates to produce hydroxyl 
radicals in the presence of hydrogen peroxide was illustrated using a hydroxyl radical assay, 
during which the decay of rhodamine B by the electron deficient radicals was monitored 
spectroscopically as a function of time.  
Table 1.3.1: IC50 values (μM) of various Cu(II) chelates against a range of human tumour cell lines. 
Complex A549a HT-29b U251c 
8AMQCu 13.4 ± 2.7 21.0 ± 4.2 7.6 ± 1.0 
PICOCu 26.04 ± 0.52 24.23 ± 1.14 11.02 ± 0.46 
SB22Cu 7.65 ± 1.13 7.53 ± 2.55 5.28 ± 5.41 
SB26Cu 21.46 ± 4.70 19.01 ± 2.52 10.77 ± 1.38 
aNon-small cell lung tumor cell line. 
bHuman colon adenocarcinoma tumor cell line.  
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Transition metal complexes may seem an odd choice for DNA molecular recognition agents. 
This is because, with few exceptions, biological transition metals are confined to coordination 
sites in proteins or cofactors, not in discrete, freestanding coordination complexes. Cells also 
generally employ organic moieties for the binding and recognition of DNA. Transition metal 
complexes, however, offer two singular advantages. Firstly, coordination complexes offer a 
uniquely modular system. The metal centre acts in essence as an anchor, holding in place a 
rigid, three-dimensional arrangement of ligands that can bear specific recognition elements. 
DNA-binding and recognition properties can thus be varied relatively easily with the facile 
interchange of ligands. Secondly, transition metal centres benefit from rich photophysical and 
electrochemical properties, thus extending their utility far beyond that of passive 
intercalation. In this case, the redox activity of the copper(II) centre is a critical aspect of the 
chemotherapeutic agent’s design.22 
Nuclease is an enzyme which has the ability to cleave the phosphodiester bonds between the 
nucleotide subunits of nucleic acids.21 Extensive research has been done using transition metal 
complexes as artificial nucleases due to the reactivity and wide range of structural features of 
these complexes. Copper(II) complexes make efficient chemical nucleases because of their 
high affinity towards neucleobases as well as their biologically accessible redox potential.  
They intercalate efficiently with DNA base pairs and show considerable nuclease activity.22 
The above discussion clearly shows the potential of Cu(II) for the synthesis of novel 
chemotherapeutic agents and reaffirms the choice of metal ion for this project.  
 
1.4 Positron Emission Tomography 
X-ray, computed tomography (CT) and magnetic resonance imaging (MRI) are medical imaging 
techniques utilised  for the visualisation of anatomical structures. In the diagnosis of certain 
diseases it is more useful to acquire images of physiological functions rather than of 
anatomical structures.23 Imaging the decay of radioisotopes bound to molecules with known 
biological properties makes acquiring such images possible.  These imaging techniques are 
more well known in nuclear medicine as positron emission tomography (PET).24 Figure 1.4.1 
highlights the production of the gamma rays used in PET imaging. PET is an imaging technique 
in which a computer-generated image of a radioactive tracer distributed in tissue is produced 
through the detection of annihilation photons. These photons are emitted when radionuclides 
are introduced into the body, decay and release positrons.25 










Figure 1.4.1: Tumour imaging with positron emission tomography (PET).25 
 
PET is a favourably sensitive, non-invasive imaging technique that is well suited for pre-clinical 
and clinical imaging of cancerous regions in the body. The imaging of target molecules which 
are associated with cancer allows for earlier diagnosis and better management of oncology 
patients.23 With recent advances in targeted drug therapy, it is now possible to design specific 
compounds to image diseased tissue in humans. PET is mostly used for the monitoring of 
cellular events in the course of a disease and during radiation or pharmacological therapy.26  
In the past, the availability of PET had been limited to the use of cyclotron-produced isotopes 
such as fluorine-18. However, the high costs of maintaining and establishing cyclotron facilities 
has led to generator based isotopes such as gallium-68 which is a key isotope. Gallium-68 has 
a half-life of 68.3 minutes and β+ = 1.89 MeV. These decay properties allowed departments 
with standard radiopharmaceutical equipment to make use of this advanced imaging 
technique. 68Ga-DOTATATE, 68Ga-DOTATOC and 68Ga-DOTANOC, shown in Figure 1.4.2 , have 




















Figure 1.4.2: Chemical structures of (a) 68Ga-DOTATOC, (b) 68Ga-DOTATATE, (c) 68Ga-DOTANOC. The highlighted 
substituents show where the variations between the three chelates lie. Image reproduced from Velikyan 
et al.28 
The research and development of metal-based radiopharmaceuticals represents a dynamic 
and fast growing research area which requires a good understanding of ligand design and 
metal coordination chemistry.23 
64Cu (t1/2 = 12.7 h; β+ 0.653 MeV, (17.8 %), β- 0.579 MeV (38.4%)) has drawn considerable 
interest in PET research owing to its commercial availability, short positron range, and 
reasonably long half-life.29 The 12.7 hour half-life of 64Cu provides the flexibility to image both 
small and large tumours. Due to the versatility of 64Cu there has been an abundance of novel 
research, primarily in the area of PET imaging.10 
Copper also has well-established coordination chemistry and a wide variety of chelator 
systems that can be linked to antibodies, proteins, peptides, and other biologically relevant 
molecules. These groups can help to increase the specificity of the copper chelates for tumour 
cells and improve their potential as PET imaging agents. 64Cu(II) has to be bound to a 
thermodynamically stable and kinetically inert ligand, which requires tracer molecules, for 
example antibodies, to be equipped with a suitable chelating moiety.26 By using radiolabelled 
tracers such as 64Cu chelates with cell targeting groups which will lead to increased 
concentration in the tissue of interest, a series of three-dimensional images can be 
reconstructed to show the size and location of a tumour. The concept of targeted 
drug/imaging agent delivery is shown in Figure 1.4.3. 












Figure 1.4.3: 64Cu chelate with receptor biomolecule attaching to a tumour receptor.24 
A recent study by Lux et al. reported the successful creation of the first metal-chelating 
nanogel imaging agent which incorporated 64Cu to be used as a PET radiotracer. 
Polyacrylamide-based (PAA) nanogels were crosslinked with a range of different polydentate 
ligands. PAA was selected as the nanogel backbone because it is stable and non-toxic. 
Experiments in mouse serum indicated that NOTA-based (1,4,7-triazacyclononane-triacetic 
acid) nanogels retained 64Cu most stably and were therefore, used along with DOTA-based  
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) nanogels for in vivo PET imaging of 
tumour-bearing mice. Figure 1.4.4 shows the 64Cu-chelated DOTA (PAA/2) and NOTA (PAA/3) 









Figure 1.4.4: 64Cu-chelated DOTA and NOTA nanogels injected into mice with resulting PET images. Image reproduced 
from Lux et al.30 
 
DOTA NOTA 
Page | 14  
 
A closer look at the PET images in Figure 1.4.5 show that after four hours, accumulation of 
PAA/3(64Cu) was visible in the liver, heart and neck blood vessels, while a moderate amount 
of signal was visualised in the tumour. PAA/2(64Cu) showed a similar pattern of uptake at four 
hours, but with a higher accumulation in the liver. Over the next 24 - 48 hours the uptake of 
PAA/3(64Cu) continued to increase. PAA/2(64Cu) showed similar trends, however, the overall 
uptake was lower than PAA/3(64Cu) after 24 and 48 hours.30 Free copper has the ability to be 
taken up by tumours via copper transporters. The study by Lux et al. also compared the 
tumour uptake of PAA/2(64Cu) and PAA/3(64Cu) to that of 64Cu-acetate. The free copper within 
tumours remained steady throughout the experiment. The higher stability of the NOTA-based 
















Figure 1.4.5: PET images comparing uptake of PAA/2(64Cu) and PAA/3(64Cu) nanogels to free 64Cu in mice containing     
subcutaneous 4T1 murine mammary carcinoma tumours. Image reproduced from Lux et al.30 
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1.5 Targeted Drug Delivery 
Taking into consideration the severe side effects of current cancer treatment, noting Cisplatin 
as an example, the main motive that continues to fuel cancer research is to improve 
therapeutic efficacy reducing the side-effects of treatment. Tumour cell-targeting systems 
have shown encouraging results in improving therapeutic efficiency.31 Target-specific delivery 
can be achieved by adding a suitable targeting moiety to the complex. Many tumour cells over-
express receptor sites for certain growth factors. By targeting these receptor sites the uptake 
of radiopharmaceuticals labelled with either 68Ga or 64Cu in neoplastic versus healthy tissue 
can be greatly enhanced.31   
Cell-targeting moieties currently in use include peptides, vitamins, antibodies, folic acid and 
integrin. Vitamin H, more commonly known as biotin, has been used as a suitable targeting 
agent in recent research.32 Biotin is a growth promoter and cancerous cells require biotin to 
sustain their rapid growth.32 The over expression of biotin receptors on the surface of 
cancerous cells make these targeted drug delivery systems an efficient method for the 
treatment of tumors.33 Previously, there has been poor overlap between the prevention, 
diagnosis and treatment of cancer which hindered efforts to effectively treat cancer. Current 
research is therefore aimed at developing a new treatment method that combines diagnosis 
and therapy.32 The combination of cell targeting groups with chemotherapeutics and isotopes 
suitable for PET imaging is therefore a very attractive area of research. 
Paclitaxel also known as Taxol, shown in Figure 1.5.1, is an effective chemotherapeutic used 
in the treatment of a wide range of cancers; however, the therapeutic effects of this drug are 
limited due to the lack of selectivity towards cancer cells and poor aqueous solubility.  A recent 
study by Heo, et al. investigated the use of gold nanoparticles as a drug delivery system for 
paclitaxel; this improved the water solubility and selectivity towards cancer cells. Beta-
cyclodextrin (a ring shaped structure with a hydrophobic inner cavity and a hydrophilic outer 
cavity) has also been successfully used to improve paclitaxel’s aqueous solubility.32 The study 
was designed to evaluate the effectiveness of diagnosis and treatment of three cancer cell 
lines using biotin-tagged gold nanoparticles as a drug delivery system for paclitaxel. The cancer 
cell lines tested were human lung (A549) carcinoma, human breast (HeLa) and human 
osteosarcoma (MG63). The impact on normal cells was determined by modified nanoparticles 
and compared to human fibroblast (NIH3T3) cell lines.32 











Figure 1.5.1: Chemical structure of Paclitaxel, more commonly known as Taxol. A highly cytotoxic compound whose   
application in chemotherapy has been improved by the addition of cell-targeting gold nanoparticles. 
 
The intracellular uptake and cytotoxicity against the three cell lines was investigated. Dark-
field microscopy analysis showed that the surface-modified gold particles had been taken into 
the cytoplasm of the cancer cell lines by biotin-receptor mediated endocytosis thus confirming 
that the biotin ligand can be used as a biomarker for cancer cell-targeted therapy. Evaluation 
of the nanoparticles anti-cancer effect in vitro showed paclitaxel has strong cytotoxic effects 
in both HeLa and NIH3T3 cells. It was noted that the mortality rate of HeLa cancer cells using 
the gold nanoparticles increased five-fold. These results confirm that gold nanoparticles 
surface-functionalised with a chemotherapeutic agent and biotin can be utilised as a carrier 
for targeted drug delivery, lessening the cytotoxic effects on healthy cells.32 
By incorporating a cellular targeting moiety such as biotin into a ligand system coordinated to 
a radionuclide, the relative uptake of the 64Cu complex in cancerous tissue compared to 
healthy cells can be enhanced allowing for both diagnosis and therapy. This would be regarded 
as a “theranostic” agent, one in which a combination of diagnostic and therapeutic capabilities 
exist in a single agent.34 
1.6 Biological Activity of N,N',O-Tridentate Schiff Base Ligands 
Schiff bases are one of the most widely used organic compounds in coordination chemistry 
finding application in the analytical, dye, food and catalysis industries.35 They have also shown 
agrochemical, fungicidal and biological activities.35 The C=N linkage in Schiff base derivatives 
has proven to be vital for biological activity.35 
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The chemotherapeutic properties of N,N',O-donor Schiff base complexes with various metals 
have been a topic of investigation in recent years.36 In particular, copper(II) Schiff base 
complexes have shown encouraging results in anticancer research. This class of copper(II) 
complexes have the ability to catalytically cleave DNA and show promising cytotoxicity 
towards certain cancer cell lines. One such study investigated the DNA cleavage, DNA binding 
and cytotoxicity of the copper(II) N,N',O Schiff base complex, [CuII(5-Cl-pap)(OAc)(H2O)]·2H2O, 










Figure 1.6.1: Structure of [CuII(5-Cl-pap)(OAc)(H2O)]·2H2O a cytotoxic copper(II)-based chemotherapeutic.36  
 
The potential binding ability of [CuII(5-Cl-pap)(OAc)(H2O)]·2H2O to calf thymus DNA was 
measured by UV spectroscopy and confirmed DNA  interactions. A strong apparent binding 
constant was calculated thus showing the potential of this class of copper(II) Schiff base 
chelates as chemotherapeutic agents. 
It was also confirmed that the complex promoted DNA cleavage. Hydrogen peroxide, singlet 
oxygen-like species and hydroxyl radicals were determined to be the active species involved 
in the DNA cleavage process. High in vitro cytotoxic properties against human cervical 
carcinoma cells (HeLa) was also observed. An IC50 = 16.123 ± 1.207 µM was measured 
confirming that this complex deserves further investigation as a possible chemotherapeutic 
drug. These data show the chelate to have a greater cytotoxicity against these specific tumour 
cell lines than the industry standard metallodrug cisplatin.36 
The induction of cell apoptosis and cytotoxicity of a copper(II) N,N',O Schiff base complex, 
[CuII(ClQP)(NO3)(H2O)], shown in Figure 1.6.2, has also been studied. The cytotoxicity of 
[CuII(ClQP)(NO3)(H2O)] was determined against the human tumour cell lines BEL-7404, HepG2, 
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NCI-H460, MGC80-3 and the normal liver cell line HL-7702. The quinoline-based Schiff base 
complex is shown to be five coordinate with the N,N',O tridentate ligand, one monodentate 










Figure 1.6.2: Structure of complex [CuII(ClQP)(NO3)(H2O)] a copper(II)-based chemotherapeutic agent.37  
Table 1.6.1 shows that [CuII(ClQP)(NO3)(H2O)] displays promising growth inhibition properties 
against four cancer cell lines with IC50 values ranging from 6.5 to 23.6 µM. The highest 
sensitivity was observed against the cancer cell line HepG2. It is interesting to note that the 
complex did not show any cytotoxicity towards the normal cell line, possibly suggesting that 
the complex is selective towards cancer cells. This study reaffirms the potential applications 
for this class of complex as antitumor agents.37 
Table 1.6.1: IC50 values against four cancer cell lines and one normal human liver cell line for [CuII(ClQP)(NO3)(H2O)]  
compared with Cisplatin.31 
Compound IC50 (µM) 
 HepG2 NCI-H460 MGC80-3 BEL-7404 HL-7702 
[CuII(ClQP)(NO3)(H2O)] 6.5 ± 0.3 23.6 ± 0.2 10.7 ± 0.3 9.8 ± 0.2 >100 
Cisplatin 8.3 ± 0.7 5.3 ± 0.4 >100 98.0 ± 17.4 80.6 ± 0.2 
 
1.7 Heteroleptic Copper(II) Complexes 
Heteroleptic complexes or mixed ligand complexes consist of transition metals with more than 
one type of ligand bound to the metal centre. This class of metal chelates has garnered 
considerable attention due to their wide range of applications in environmental, industrial and 
medicinal research.38 The effect of one ligand on the co-ligand through the central metal atom 
in heteroleptic complexes has proven to be very important in coordination chemistry.38 The 
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interactions between the two co-ligands can be observed in thermodynamic and kinetic 
aspects of chemical reactivity. In particular, copper(II) complexes with Schiff base ligands have 
shown increased bioactivity in the presence of bidentate nitrogen-donor heterocyclic ligands 
such as 1,10-phenanthroline (phen) and 2,2-bipyridyl (bpy). Several studies have investigated 
the versatile DNA cleavage capabilities, cytotoxicity and antioxidant activity of heteroleptic 
copper(II) Schiff base complexes.38    
The antioxidant and DNA binding affinities were determined for a range of eight heteroleptic 
Schiff base complexes with  phen and bpy as co-ligands.39 The most biologically active complex 
[CuL2(phen)](ClO4)2, shown in Figure 1.7.1, contained a hydrophobic methyl substituent. This 
is an interesting result as it has been shown in other studies that the lipophilicity of metal 
chelates, particularly those that exert their cytotoxicity through DNA binding, is a critical 
physico-chemical predictor for chemotherapeutic activity.40 The antioxidant activity of 
[CuL2(phen)](ClO4)2 against DPPH, which is a stable radical used for studying radical scavenging 
activity, showed antioxidant activity very similar to the industry standard antioxidant,  










Figure 1.7.1: Heteroleptic complex [CuL2(phen)](ClO4)2 which has shown antioxidant properties.32 
 
DNA binding studies have showed the metal complex binds with nucleic acids through 
covalent and/or non-covalent interactions. Non-covalent interactions are most prevalent with 
heteroleptic complexes and can occur as electrostatic interactions, intercalation and groove 
(major or minor) binding. [CuL2(phen)](ClO4)2 had a DNA binding constant of 3.63 x 104 M-1. 
Due to the hydrophobic interactions of the methyl group with the hydrophobic DNA surface, 
the above complex showed higher binding affinity than complexes with other substituents.38  
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 It has similarly been shown that an N,N',N'' tridentate, heteroleptic complex  
[Cu(L1)(2,9-dmp)](ClO4)2, shown in Figure 1.7.2, exhibits favourable affinity towards calf 
thymus DNA as well as cytotoxic activity against MCF-7 breast cancer cells lines. The N,N',N'' 
ligand diethylenetriamine is expected to show various DNA binding interactions while the  
co-ligand 2,9-dimethyl-1,10-phenanthroline has been reported to be a copper dependant 











Figure 1.7.2: Structure of the tridentate, heteroleptic complex [Cu(L1)(2,9-dmp)](ClO4)2 with 2,9-dimethyl-1,10-
phenanthroline.32 
[Cu(L1)(2,9-dmp)](ClO4)2 has a DNA binding constant of 2.1 x 104 M-1 due to partitial insertion 
of the complex between DNA base pairs. It was proposed that [Cu(L1)(2,9-dmp)](ClO4)2  had a 
higher binding constant compared to the other complexes in the study due to reduced steric 
hinderance of the primary ligand. Furthermore, strong hydrogen bonding of the NH2 and NH 
groups of diethylenetriamine with phosphate groups or nucleobases of the DNA could 
stabilise the DNA/drug conjugate and contribute to the higher binding constant.39  
Cell screening studies were carried out against MCF-7 breast cancer cell lines and a 
comparative study against the ubiquitous cisplatin was conducted. The complex  
[Cu(L1)(2,9-dmp)](ClO4)2 had an IC50 value of 16.7 ± 1.5 µM after 24 hours and 11.3 ± 1.1 µM 
after 48 hours showing higher cytotoxicity than cisplatin. The enhanced hydrophobicity of the 
complex due to the co-ligand seemingly aids in the transport of the complex through cell 
membranes which leads to efficient apoptosis of the cells.39 
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1.8 DNA Binding Modes 
As the primary pharmacological target of many antitumor drugs is DNA, DNA binding affinities 
of metal complexes are of paramount importance for the development of effective 
metallodrugs.36 There exist a number of commonly encountered binding modes. Molecules 
can bind covalently to the DNA bases, as with cisplatin. Molecules also have the ability to bind 
to the sugar-phosphate backbone of DNA. Metalloinsertors contain an aromatic planar ligand 
which extends into the base stack upon DNA binding and ejects the bases of a single base-
pair. The planar ligand of the chelate acts as π-stacking replacement in the DNA base stack. 
DNA intercalators are another DNA binding agent, which partially unwind the DNA and π-stack 
between two base pairs. Groove binding occurs when molecules bind into the major or minor 
grooves of the DNA by hydrophobic interactions or by partial intercalation.22  
The three main DNA binding modes of metal chelates are groove binding, intercalation and 
insertion. All three binding modes are illustrated in Figure 1.8.1. 
 
 
Figure 1.8.1: Illustration of DNA binding modes: insertion, intercalation and groove binding.22 
The study of the interactions between transition metal complexes and DNA is a field that is 
still under investigation. Research on DNA cleavers is important since they can be used as 
chemotherapeutic agents and DNA structural probes.38 In most cases DNA binding is a key 
step for DNA cleavage, highlighting the significance of research in this field. 
Page | 22  
 
DNA intercalators are usually small metal complexes or organic molecules which partially 
unwind the DNA helix. Metallointercalators are small metal chelates with at least one 
intercalating ligand. These ligands are positioned parallel to the base pairs and protrude away 
from the metal centre and can readily stack in the DNA helix. They enter the double helix via 
the major groove, with the intercalating ligand acting as a new base pair. This binding mode 
leads to minimal distortion of the tertiary structure of the DNA and is illustrated in  










Figure 1.8.2: Crystal structure of a rhenium-based metallointercalator showing Van der Waals and hydrogen interactions. 
Copper(II) complexes in particular interact with DNA via covalent bonding, electrostatic 
interaction, hydrogen bonding with ligands, intercalation and groove binding.41 Copper(II) 
complexes have been known to bind and cleave double-stranded DNA with high reactivity and 
structural selectivity. Interactions of smaller compounds in the minor groove of DNA is 
different from those occurring in the major groove. This is due to steric hindrance and 
electrostatic potential due to the minor groove binder’s narrow shape.41  
Groove binding is an intermolecular interaction between the complex and DNA helix which 
does not alter the DNA structure in any way and to a large extent the structure of the metal 
compounds will determine whether the complex will favour the minor or major groove. 
 
 











Figure 1.8.3: (A) A molecule docked into the minor groove and (B) into the major groove of the DNA helix.42 
Copper(II) phenanthroline complexes are one of the most studied copper complexes in terms 
of biological activity.43 Numerous studies on this class of complex suggest they non-covalently 
bind to the minor groove of double-stranded DNA. An example of a heteroleptic copper 
complex, [CuL2(phen)] with a phenanthroline co-ligand, which favours groove binding, is 














Figure 1.8.4: Structure of [CuL2(phen)]: a known DNA groove binder.35 
A less pronounced bathochromic shift in the UV absorption titration experiments of the above 
complex suggested the possibility of groove binding. Further studies to confirm the predicted 
binding mode were carried out using viscosity titrations. These titrations not only elucidate 
the binding mode, but also determine the affinity of the complex for calf-thymus DNA.  
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Intercalation involves the DNA double helix being “stretched out” to accommodate the 
binding ligands in between base pairs and results in an increase in viscosity. Partial 
intercalation results in the DNA bending thus shortening the helix and resulting in a reduced 
viscosity. Groove binding is confirmed by little to no change in the viscosity of the solutions 
since minimal changes occur to the double-stranded DNA helix. Viscosity measurements 
showed very slight changes suggesting partial intercalation and predominantly minor groove 
binding.43 
1.9 Objectives 
The aim of this project is to synthesise a series of single-ligand and heteroleptic copper(II) 
Schiff base chelates which are anticipated to be chemotherapeutic agents. Both N,N',O and 
N,N',N'' Schiff base ligands were synthesised to investigate any variation in bioactivity. The 
addition of a co-ligand to the above mentioned complexes is used to investigate whether the 
heteroleptic copper(II) chelates show increased bioactivity compared to the single-ligand 
copper(II) chelates. 
The following objectives for the project have been identified from the literature review: 
The project will commence with the synthesis of the primary Schiff base ligands depicted in 
Figure 1.9.1. The ligands (where possible) will be characterised by 1H and 13C NMR 
experiments, FT-IR spectroscopy and mass spectrometry. 















Figure 1.9.1: Proposed ligands to be chelated to copper(II) in this study. 
Once the Schiff base ligands have been successfully synthesised and characterised, they will 
be coordinated to copper(II). The metal chelates will be characterised by UV/visible and FT-IR 
spectroscopy, mass spectrometry and, where possible, X-ray crystallography. 
The copper(II) complex of the N,N',O Schiff base ligand will be further reacted with various  
co-ligands to form a range of heteroleptic complexes. The co-ligands used in the synthesis of 
the heteroleptic complexes include 2,2’-Bipyridyl, 1,10-Phenanthroline, 
5-amino-1,10-phenanthroline and Phen-biotin the latter is illustrated in Figure 1.9.1 [d] . The 



































Figure 1.9.2: Proposed heteroleptic copper(II) complexes to be synthesised in this study. 
Computational studies will be performed on all copper(II) metal chelates using Density 
Functional Theory. Comparisons will be drawn between the experimental and calculated data 
to expand the understanding of the experimental data. 
The DNA binding affinities will be determined by a competitive titration with ethidium 
bromide. The cytotoxicity will be investigated by screening against a panel of four human 
tumour cell lines. The ability of the copper(II) complexes to catalyse the production of hydroxyl 
radicals will also be explored. 
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The anticipated outputs of this project include the synthesis of a range of anticancer agents. 
Incorporating biotin into the ligand design will allow for cell targeting potentially leading to an 
increase in the uptake of the metal chelates in neoplastic versus healthy cells. Radiolabelling 
the compounds with 64Cu will have potential for PET imaging.  
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Chapter 2 | Experimental 
2.1 General Methods and Instrumentation  
All starting materials used in the syntheses were purchased from Sigma–Aldrich (Germany) 
and used as received. Organic solvents were purchased from Merck (South Africa) and were 
of analytical reagent (AR) grade. All solvents were dried using a Puresolv™ MD 7 purification 
system from Innovative Technologies prior to use. NMR spectra were recorded with a Bruker 
Avance III 400 MHz spectrometer equipped with a Bruker magnet (9.395 T) using a 5 mm TBIZ 
probe at frequencies of 400 MHz and 100 MHz for the 1H and 13C spectra, respectively. The 
spectra were recorded at 30 0C. All NMR experiments were conducted using Bruker Topspin 
2.1, patch level 6. All proton and carbon chemical shifts are quoted relative to CDCl3:  
1H, 7.26 ppm and 13C, 77.16 ppm and DMSO-d6: 1H, 2.50 ppm and 13C, 39.52 ppm. 
 
FTIR spectra were recorded using a Bruker Alpha FTIR spectrometer equipped with an ATR 
platinum Diamond 1 reflectance accessory. The machine acquired the information in 32 scans 
with a spectral resolution of 1.0 cm-1. The abbreviations used in the text are as follows; br, 
broad; s, strong; m, medium and w, weak signals. Elemental analysis was carried out using a 
CHNS-O Flash 2000 Organic Elemental Analyser. Electronic spectra were recorded using a 
Shimadzu UVPC-1800 double beam UV–Vis scanning spectrometer (1.0 cm path length 
cuvette).  Spectra were recorded from 800 to 200 nm. High resolution masses were 
determined with a Waters Acquity-LCT Premier coupled high performance liquid 
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2.2 Synthesis of Ligands 
 





Figure 2.2.1: Structure of 2-[(E)-(quinolin-8-ylimino)methyl]phenol showing the atom numbering scheme. 
HL1 was prepared by the condensation of salicylaldehyde with 8-aminoquinoline in ethanol. 
To a solution of 8-aminoquinoline (0.83 g, 5.78 mmol) in ethanol (30 mL) was added 
salicylaldehyde (0.61 mL, 5.78 mmol) and the solution heated to reflux for four hours. The 
solvent was removed from the orange reaction mixture under reduced pressure using rotary 
evaporation. The resulting orange oil was recrystallized from hexane to afford orange/red 
crystals. Yield (1.26 g, 87 %). 
 
The following characterisation data were recorded:  
1H NMR (400 MHz, CDCl3, 303K) [δ, ppm]: 13.93 (s, 1H, OH); 9.01 (dd, 1H, J1 = 4.26 Hz, J2 = 1.75 
Hz, 8); 8.96 (s, 1H, 7); 8.21 (dd, 1H, J1 = 8.26, J2 = 1.72, 10); 7.74 (dd, 1H, J1 = 8.18, J2 = 1.27, 
12); 7.33-7.62 (m, 5H, 3, 5, 9, 13, 14); 7.10 (d, 1H, 4); 6.97 (m, 1H, 2). 13C NMR (100 MHz, CDCl3, 
303 K) [δ, ppm]: 164.76 (C-1); 162.06 (C-7); 150.49 (C-15); 145.59 (C-8); 142.38 (C-16); 135.98 
(C-10); 133.28 (C-3); 132.35 (C-5); 129.22 (C-11); 126.57 (C-13); 126.17 (C-14); 121.73 (C-12); 
119.61 (C-6); 118.98 (C-9); 118.78 (C-4); 117.63 (C-2). 
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Figure 2.2.2: Structure of (E)-1-(pyridin-2-yl)-N-(quinolin-8-yl)methanimine showing the atom numbering scheme. 
8-aminoquinoline (0.20 g, 1.39 mmol), pyridine-2-carboxaldehyde (0.15 g, 1.39 mmol) and a 
catalytic amount of piperidine (1 drop) were heated to reflux for two hours in ethanol (20 mL). 
The solvent was removed via rotary evaporation under reduced pressure, yielding an orange 
oil. Yield (0.32 g, 97%). 
 
 
The following characterisation data were recorded: 
1H NMR (400 MHz, CDCl3, 298 K) [δ, ppm]: 6.95 (m, 1H, 13); 7.17 (m, 1H, 8); 7.37, 
(m, 2H, 2, 12); 7.55 (m, 1H, 4);  7.90 (m, 1H, 3); 8.01 (m, 1H, 9); 8.10 (m, 1H, 1); 8.81 (m, 2H, 7, 
11); 10.12 (s, 1H, 6). 13C NMR (100 MHz, CDCl3, 303 K) [δ, ppm]: 150.24 (C-6); 147.43 (C-7); 
143.97 (C-14); 138.47 (C-1); 137.47 (C-5); 137. 06 (C-15); 135.99 (C-4); 134.66 (C-9); 128.88  
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2.2.3 Synthesis of 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-N-   







Figure 2.2.3:  Structure of 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-N-(1,10-phenanthrolin-5-yl) showing the 
atom  numbering scheme. 
Biotin (0.220 g, 0.90 mmol) was stirred in thionyl chloride (5 mL) in a flame-dried, two-neck 
round bottomed flask. The reaction was stirred for one hour, after which the thionyl chloride 
was removed in vacuo. The resulting yellow residue of biotin acyl chloride was redissolved in 
dry acetonitrile (10 mL). 5-amino-phenanthroline (0.195 g, 1.00 mmol) and DMAP  
(0.122 g, 1.00 mmol) were dissolved in dry acetonitrile (15 mL) in a separate flame-dried,  
two-neck round bottom flask. The biotin acyl chloride solution was added via cannula transfer 
to the amine solution and allowed to stir at room temperature overnight. An orange 
precipitate was collected via centrifugation and purified by column chromatography on 
neutral alumina using methanol as the eluent. The methanol was removed via rotary 
evaporation, yielding the final product. Yield (0.20 mg, 21%). 
The following characterisation data were recorded: 
 1H NMR (400 MHz, DMSO, 298 K) [δ, ppm]: 10.10 (s, 1H, NH); 9.15 (dd, 1H, J1 = 4.32, J2 = 1.63, 
10); 9.05 (dd, 1H, J1 = 4.27, J2 = 1.69, 3); 8.63 (dd, 1H, J1 = 8.45, J2 = 1.51, 1); 8.48  
(dd, 1H, J1 = 8.26, J2 = 1.53, 8); 8.20 (s, 1H, 5); 7.81 (dd, 1H, J1 = 8.38, J2 = 4.24, 9); 7.77 (dd, 1H 
J1 = 8.15, J2 = 4.39, 2); 6.42 (d, 1H, Biotin, NH), 6.35 (d, 1H, Biotin, NH), 4.32 (m, 1H, 21); 4.17 
(m, 1H, 19); 3.12 (m, 1H, 18); 2.85 (m, 1H, 22); 2.61 (m, 1H, 22); 1.75 (m, 2H, 14); 1.65-1.27 
(m, 6H, 15, 16, 17). 13C NMR (100 MHz, DMSO-d6, 303 K) [δ, ppm]: 172.89 (C-13); 163.19  
(C-20); 150.31 (C-11); 149.67 (C-10); 146.25 (C-1); 144.29 (C-6); 136.25  (C-3); 132.27 (C-8); 
132.07 (C-4); 128.48 (C-12); 125.08 (C-5); 124.00 (C-9); 123.34 (C-7); 120.62 (C-2); 61.57  
(C-19); 61.50 (C-21); 59.76 (C-18); 55.87 (C-22); 28.81 (C-14); 28.60 (C-16); 25.95 (C-15); 25.45 
(C-17). ES+: 444.0945 m/z (M+Na)+ 
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Figure 2.2.4: Structure of N-(1,10-phenanthrolin-5-yl)propionamide ligand showing the atom numbering scheme. 
Propionic acid (0.11 mL, 1.5 mmol) and thionyl chloride (0.07 mL, 1.0 mmol) in anhydrous 
dichloromethane (5 mL) were stirred for one hour under an inert atmosphere in a two-necked 
round bottom flask. In parallel, 5-amino-phenanthroline (0.20 g, 1.0 mmol) and DMAP  
(0.13 g, 1.0 mmol) were stirred in anhydrous dichloromethane under nitrogen for one hour in 
a two-necked round bottom flask. The propionic acid reaction mixture was slowly added by 
cannula transfer to the phenanthroline amine solution and the resulting reaction mixture 
stirred under nitrogen overnight. An orange precipitate was collected via centrifugation and 
purified by column chromatography on neutral alumina eluted with methanol. The methanol 
was removed via rotary evaporation, yielding the final product.  Yield (0.32 mg, 29%). 
 
The following characterisation data were recorded: 
1H NMR (500 MHz, DMSO, 298 K) [δ, ppm]: 10.08 (s, 1H, NH); 9.13 (dd, 1H, J1 = 4.32, J2 = 1.63, 
10); 9.03 (dd, 1H, J1 = 5.66 J2 = 2.67, 3); 8.62 (d, 1H, 1); 8.44 (d, 1H, 8); 8.18 (s, 1H, 5); 7.83  
(dd, 1H, J1 = 12.65, J2 = 4.26, 9); 7.74 (dd, 1H, J1 = 12.51, J2 = 3.81, 2); 2.56 (m, 2H, 14);  
1.20 (t, 3H, 15). 13C NMR (100 MHz, DMSO-d6, 303 K) [δ, ppm]: 173.62 (C-13); 150.36 (C-11); 
149.72 (C-10); 146.33 (C-1); 144.24 (C-6); 136.25 (C-3); 132.32 (C-8); 132.17 (C-4); 128.58  
(C-12); 125.18 (C-5); 123.99 (C-7); 123.28 (C-9); 120.44 (C-2); 29.61 (C-14); 10.31 (C-15).  
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2.3 Synthesis of Copper(II) Complexes 
 
2.3.1  Synthesis of dichloro-(E)-1-(1,6-dihydropyridin-2-yl)-N-(1,2dihydropyridin-










Figure 2.3.1: Structure of dichloro-(E)-1-(1,6-dihydropyridin-2-yl)-N-(1,2-dihydropyridin-2-ylmethyl)methanimine 
copper(II). 
 
This complex was synthesised via a templating reaction. Picolylamine (0.20 g, 1.85 mmol) was 
dissolved in ethanol (15 mL) and stirred. To this solution copper(II) chloride dihydrate  
(0.32 g, 1.85 mmol) dissolved in ethanol (5 mL) was added dropwise resulting in a deep blue 
precipitate. Pyridine-2-carboxaldehyde (0.20 g, 1.85 mmol) was dissolved in ethanol (5 mL) 
and added dropwise to the reaction solution. The resulting mixture was stirred at room 
temperature for two hours yielding a deep green precipitate. The final product was collected 
via vacuum filtration and washed with cold ethanol. Yield (0.34 g, 56%). 
 
 
The following characterisation data were recorded:  
FT-IR (cm-1): 765 ν(C-H), 1346 υ(C=C), 1597 ν(C=N), 3072 ν(C-H). UV (λmax, ε) [nm, M-1 cm-1]: 
273, 14026. ES+: 288.9830 m/z (M + Na)+. Elemental analysis: Calculated for 
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Figure 2.3.2: Structure of dichloro-(E)-1-(pyridin-2-yl)-N-(quinolin-8-yl)-methanimine copper(II) [Cu(L2)(Cl2)]. 
The ligand L2 (0.32 g, 1.39 mmol) was dissolved in ethanol and copper(II) chloride dihydrate 
(0.24 g, 1.39 mmol) dissolved in a minimum volume of ethanol was added. The reaction 
mixture was heated to reflux for two hours yielding a green precipitate which was collected 
by gravity filtration. The complex was re-crystallised from methanol/diethyl ether.  
Yield (0.49 g, 95%). 
 
 
The following characterisation data were recorded:  
FT-IR (cm-1): 767 ν(C-H), 1496, ν(C=C), 1598 ν(C=N), 2994 ν(C-H).  UV (λmax, ε) [nm, M-1 cm-1]:  
232, 17991; 354, 46402; 369, 19917. ES+: 331.0052 m/z (M-Cl)+. Elemental analysis: Calculated 
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Figure 2.3.3: Structure of (chloro)-(1-(((quinolin-8-yl)imino)methyl)-2-naphtholato) copper(II), [Cu(L1)(Cl)]. 
 
To a solution of HL1 (1.26 g, 5.07 mmol) dissolved in ethanol (40 mL) was added a solution of 
CuCl2·2H2O (0.86 g, 5.07 mmol) dissolved in ethanol (20 mL) and the mixture heated to reflux 
for three hours. The solution was cooled to room temperature and the dark green  
semi-crystalline precipitate collected via gravity filtration and washed with cold ethanol  
(20 mL). Yield (1.63 g, 93 %). 
 
The following characterisation data were recorded:  
FT-IR (cm-1): 1605 ν(C=N), 1204 ν(C=C), 1435 ν(C=C), 823 ν(C-H), 746 ν(C-H).  
UV (λmax, ε) [nm, M-1 cm-1]: 228, 34040; 330, 12710; 420, 10342. ES+: 310.0118 m/z (M-Cl)+ 
Elemental analysis: Calculated for C16H11ClCuN2O·H2O: C, 52.75; H, 3.60; N, 7.69.  
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2.3.4  Synthesis of (2,2'-Bipyridine)-(2-(((quinolin-8-yl)imino)methyl)phenolato)  
copper(II) chloride [Cu(L1)(Bpy)](Cl) 
 
 
Figure 2.3.4: Structure of (2,2'-Bipyridine)-(2-(((quinolin-8-yl)imino)methyl)phenolato) copper(II)chloride [Cu(L1)(Bpy)(Cl)]. 
 
To a solution of [Cu(L1)(Cl)] (0.10 g, 0.29 mmol) dissolved  in 5:1 THF/H20 (25 mL) was added 
a solution of 2,2’-bipyridyl (45 mg, 0.29 mmol) in THF (15 mL) and the mixture heated to reflux 
for three hours followed by stirring at room temperature overnight. The solution was then left 
undisturbed and over two days dark green crystals formed. Yield (0.11 g, 76%). 
 
 
The following characterisation data were recorded: 
 
FT-IR (cm-1): 1602 v(C=N) ; 1437 ν(C=N); 1149 ν(C=C); 759 ν(C-H). UV (λmax, ε) [nm, M-1 cm-1]: 
228, 42595; 283, 17308; 330, 12429; 420, 9977. ES+: 466.0814 m/z (M+). Elemental analysis: 
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2.3.5 Synthesis of (1,10-phenanthroline)-(2-(((quinolin-8-yl)imino)methyl) 




Figure 2.3.5:  Structure of (1,10-phenanthroline)-(2-(((quinolin-8-yl)imino)methyl)phenolato) copper(II) chloride 
[Cu(L1)(Phen)(Cl)]. 
 
To a solution of [Cu(L1)(Cl)] (0.10 g, 0.29 mmol) dissolved in 5:1 THF/H20 (25 mL) was added a 
solution of 1,10-phenanthroline (52 mg, 0.29 mmol) in THF (15 mL) and the mixture heated to 
reflux for three hours and then allowed to stir at room temperature overnight. The solvent 
was removed in vacuo yielding a dark green precipitate. The complex was crystalised from 
water via slow evaporation and the dark green crystals were collected by gravity filtration. 
Yield (0.12 g, 79%). 
 
The following characterisation data were recorded:  
 
FT-IR (cm-1): 1603 ν(C=N); 902 ν(C-H); 836 ν(C=C); 723 ν(C=C). ES+: 489.9890 m/z (M+).  
UV (λmax, ε) [nm, M-1 cm-1]: 226, 67497; 269, 37222; 330, 13970; 420, 10751. Elemental 
analysis: Calculated for C28H19ClCuN4O·3H2O: C, 57.93; H, 4.43; N, 9.65.  




Page | 38  
 
2.3.6 Synthesis of (1,10-phenanthroline-5amine)-(2-(((quinolin-8-yl)imino) 











Figure 2.3.6: Structure of (1,10-phenanthroline-5-amine)-(2-(((quinolin-8-yl)imino)methyl) phenolato)-copper(II) chloride 
[Cu(L1)(Phen-NH2)](Cl). 
 
To a solution of [Cu(L1)(Cl)] (0.10 g, 0.29 mmol) in 5:1 THF/H20 (25 mL) was added a solution 
of 1,10-phenanthroline-5-amine (52 mg, 0.29 mmol) in THF (15 mL) and the mixture heated 
to reflux for three hours and then allowed to stir at room temperature overnight. The solvent 
was removed in vacuo yielding a dark green precipitate. The complex was crystalised from 
water via slow evaporation and the dark green crystals collected by gravity filtration and 
washed with cold THF. Yield (99 mg, 79%). 
 
 
The following characterisation data were recorded: 
 
FT-IR (cm-1): 1600 ν(C=N) ; 1460 ν(C-H); 1401 ν(C-H); 832 ν(C=C). ES+: 504.9900 m/z (M+).  
UV (λmax, ε) [nm, M-1 cm-1]: 226, 54180; 250, 35670; 287, 27722; 332; 15982; 418, 9734. 
Elemental analysis: Calculated for C28H20ClCuN5O·H2O: C, 60.11; H, 3.96; N, 12.52.  
(Found: C, 59.75; H, 3.78; N, 11.95).  
 
Page | 39  
 
Chapter 3 | Synthesis 
 3.1 Synthesis of Schiff Base Ligands 
 
A common feature in many of the ligands synthesised in this work is imine bonds. Imines are 
formed by a reaction between a ketone or aldehyde with a primary amine and are 
characterised by a carbon-nitrogen double bond. The imine formed by the reaction of a 
carbonyl and primary amine is often referred to as a Schiff base.44 A general scheme for the 





Figure 3.1.1: General reaction scheme for Schiff base formation.44 
 
The first step in the mechanism for Schiff base formation involves attack of the carbonyl 
carbon by the nitrogen of the amine. This is followed by proton transfer from the ammonium 
ion to the alkoxide group. This forms a neutral tetrahedral intermediate, called a 
carbinolamine, which exists is equilibrium with two protonated forms. Protonation can take 
place on either the oxygen or nitrogen atom. Water is eliminated from the  
oxygen-protonated intermediate resulting in a protonated imine which then loses a proton 
forming a double bond between the nitrogen and carbon.44 This reaction mechanism is 

























Figure 3.1.2: Reaction mechanism for the acid-catalysed synthesis of (E)-2-((quinolin-8-ylimino)methyl)phenol. 
 
3.2 Biotin Acyl Chloride Formation 
Of the numerous classes of carbonyl compounds, carboxylic acids are one of the most 
commonly available and inexpensive acids both in biological systems and in the laboratory.44 
A drawback of carboxylic acids is that they are relatively unreactive towards nucleophilic acyl 
substitution reactions. This is due to the carboxylic acid’s OH group being a poor leaving group 
as it is a strong base.44 As a result of this decreased reactivity, chemists need to activate the 
carboxylic acids to promote nucleophilic acyl substitution reactions. Considering all carboxylic 
derivatives, acyl halides are the most reactive. Carboxylic acids can be converted to acyl 
chlorides by reaction with phosphorus trichloride (PCl3), thionyl chloride (SOCl2), oxalyl 
chloride (COCl)2, phosphorus oxychloride (POCl3) or phosphorus pentachloride (POCl5).45 A 
general scheme for the conversion of a carboxylic acid to an acyl chloride using thionyl chloride 
is shown in Figure 3.2.1. 





Figure 3.2.1: General reaction scheme for acyl chloride formation from a carboxylic acid using thionyl chloride.44 
In the above reaction, thionyl chloride acts as both the solvent and reagent in the conversion 
of the carboxylic acid to acyl chloride. In the presence of moisture, the acyl chloride is very 
susceptible to hydrolysis back to the carboxylic acid.44 Therefore, the product of this reaction 
was not isolated and characterised due to its high sensitivity and was used directly in the next 
step. This procedure was used to activate the carboxylic acid group of biotin (Figure 3.2.2) to 














Figure 3.2.2: Reaction mechanism for the formation of 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) 
    pentanoylchloride.46 
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The conversion of biotin to the biotin acyl chloride derivative proceeds through a  
[1,2]-addition reaction of the chloride ion to the carbonyl carbon followed by a  
[1,2]-elimination reaction which yields the acyl chloride, HCl and SO2. The reaction proceeds 
by a nucleophilic attack on thionyl chloride by the carbonyl group of the carboxylic acid. This 
is followed by the removal of a chloride (the leaving group) resulting in a chlorosulfite species. 
The carbonyl group then undergoes nucleophilic attack by the chloride ion. SO2 and a chloride 
ion are removed in the next step and lastly deprotonation forms HCl and leaves the biotin acyl 
chloride derivative.44, 46 
 
3.3 Amide Bond Formation 
 
Amides are common compounds featured in both small and complex, natural and synthetic 
molecules.47 According to the Comprehensive Medicinal Chemistry Database, the 
carboxamide functional group is found in more than 25% of known drugs.47 This is due to 
favorable properties of amides such as being stable under physiological conditions, they are 
neutral and they possess both hydrogen-bond accepting and donating properties which can 
potentially stabilise drug/target conjugates. The formation of an amide bond can be achieved 
using various methods. In this work it is a result of reacting the desired amine and an acyl 
chloride. A base, such as 4-dimethylaminopyridine (DMAP), is required to firstly trap the HCl 
formed and to accelerate the reaction. The HCl must be trapped to prevent the conversion of 
the amine into its unreactive hydrochloride salt.45 A general scheme for the synthesis of an 




Figure 3.3.1: General reaction scheme for amide formation from acyl chloride.44 
 
The mechanism for the formation of the biotin-tagged co-ligand which features an amide 
bond is illustrated in Figure 3.3.2. 












Figure 3.3.2: Reaction mechanism indicating amide bond synthesis in the formation of 5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)-N-(1,10-phenanthrolin-5-yl)pentanamide.44, 45 
 
The reaction between the acyl chloride and amine was carried out at room temperature due 
to the high reactivity of the acyl chloride and proceeded via the following mechanism: the 
reaction firstly undergoes an addition step followed by an elimination. The carbonyl carbon 
on the acyl chloride undergoes nucleophilic attack by the amine nitrogen atom forming a 
tetrahedral ammonium species. The elimination stage occurs in a two-step process, firstly the 
carbon-oxygen double bond reforms and the chloride ion is eliminated. This is followed by the 
elimination of the proton from the ammonium ion which can be removed by either the 
chloride ion (producing HCl) or by a second amine (DMAP in this context) forming an 
ammonium chloride species.45 
 
3.4 Synthesis of Metal Chelates 
The metal chelates synthesised in this project comprise three single-ligand Schiff base 
complexes and three heteroleptic Schiff base complexes. All complexes were coordinated to 
copper(II) chloride. The metalation procedure involved refluxing the Schiff base ligands with 
the copper(II) metal salt in a 1:1 mole ratio in a polar solvent. The reaction mechanisms in 
Figure 3.4.1 illustrates the formation of the single-ligand complexes. 










Figure 3.4.1: Reaction illustrating the general synthetic method used for metalation of the Schiff base ligands in this work. 
Reaction of the neutral tridentate Schiff base ligands with copper(II) chloride yields a square 
pyramidal complex with the coordination sites occupied by the tridentate ligand and two 
monodentate chloride ligands. The coordination of the monoanionic tridentate ligand leads 
to a neutral square planar complex with the coordination sites occupied by the tridentate 
ligand and a single chloride ligand. 
The three heteroleptic complexes were then synthesized by adding a stoichiometric amount 
of the desired co-ligand to the square planar copper(II) chelate (designated A in Figure 3.4.1) 
in a 1:1 mole ratio in a 5:1 THF/H20 solvent system. In this process, the inner sphere chloride 
ligand is displaced by a neutral bidentate ligand leading to a square pyramidal cationic chelate. 
This chelate is isolated as the chloride salt.  The general reaction procedure for formation of 
the heteroleptic complexes is shown in Figure 3.4.2. The three co-ligands used were  
2,2’-bipyridyl, 1,10-phenanthroline and 1,10-phenanthroline-5-amine.  














Figure 3.4.2: Reaction mechanism for the synthesis of the heteroleptic copper(II) complexes. 
 
All complexes in this study are water soluble and were recrystallized either from water, 
methanol or THF. The solvent system of 5:1 THF/H20 was used due to complex A only being 
partially soluble in methanol and THF. This resulted a mixture of products and the reaction not 
going to completion. The solvent system 5:1 THF/H20 produced the desired complexes in good 
yields and high purity.  
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Chapter 4 | Spectroscopy 
4.1 The Electromagnetic Spectrum 
Spectroscopy refers to a branch of science which investigates the spectra produced when 
atoms, molecules or ions interact with or emit electromagnetic radiation. Energy is exchanged 
when electromagnetic radiation interacts with matter. Atoms and molecules may absorb this 
energy. When these atoms and molecules return to their normal, more stable energy states, 
they emit radiation in various parts of the electromagnetic spectrum. Both the absorbed and 
emitted radiation can give insight into the structure of molecules and atoms. The 
electromagnetic spectrum extends from high-frequency (short wavelength) gamma rays of 
1020 Hz to low-frequency (long wavelength) radio waves of 108 Hz.48 Table 4.1.1 shows the 
various regions of the electromagnetic spectrum which are of interest in chemical analysis. 
Table 4.1.1: Regions of the electromagnetic spectrum of interest in chemical analysis.49  
Radiation Use in chemistry 
Gamma rays Emitted in radioactive decay 
X-rays Diffraction of X-rays used to determine molecular structures. 
Ultraviolet Absorption spectra used for molecule electronic structure 
determination. 
Visible Emission and absorption spectra used for quantitative and 
qualitative identification of elements. 
Infrared Absorption spectra used for structure determination. 
Radiowaves Absorption at accurately measured frequencies used to 
determine molecule structure (NMR, EPR). 
 
Gamma and X-rays interact with electrons and atomic nuclei of molecules while visible light 
and ultraviolet radiation interact with the electrons of a compound. Infrared energy is 
absorbed and increases the motion of atoms in a molecule relative to each other and 
radiowaves interact with the electronic spin of the electrons in a compound. Figure 4.1.1 
shows a summary of the electromagnetic spectrum’s wavelengths and how they interact with 
matter. 
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                       400 nm                      700 nm 
Figure 4.1.1: Summary of wavelengths of the electromagnetic spectrum and their applications in molecular spectroscopy.  
In this study, a range of spectroscopic techniques were used to characterise and study the 
metal chelates and free ligands. The techniques include X-ray crystallography, UV/vis 
absorption, infrared, Nuclear Magnetic Resonance (NMR) and fluorescence spectroscopy as 
well as mass spectrometry.  
 
4.2 Infrared (IR) Spectroscopy 
4.2.1 Introduction 
Infrared radiation is lower in frequency than that of visible light. The IR radiation of most 
interest in chemical analysis ranges in wavenumbers from 400-4000 cm-1. It is wellknown that 
the atoms in a molecule are constantly moving with the bonds bending and stretching. Each 
bending and stretching vibration in a molecule proceeds with a characteristic frequency.  
When a molecule is radiated with photons of a frequency that correlates with the frequency 
of a vibration or bending mode of a certain bond, the molecule will absorb energy which will 
intensify the bending and stretching. This yields an IR spectrum. By measuring the 
wavenumbers of the absorbed energy, it is possible to determine what kind of bonds or 
functional groups exist in a given compound.49, 50  
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The vibrational frequency of a particular bond is characteristic of the two bonded atoms. It is 
also influenced by the surrounding bonds of that molecule. The IR spectra of any given 
compound therefore gives information about what functional groups are present in that 
molecule along with how these functional groups are positioned relative to one another. 
Rotations in a compound, elemental vibrations and electron movements within a compound 
can all be detected with IR spectroscopy.48 
4.2.2 Results and Discussion 
In this study of heteroleptic complexes, IR spectroscopy was employed to firstly investigate 
the shifts in peaks of the co-ligands after chelation to copper(II) and secondly the C=N 
stretching and C-H aromatic bending of the primary ligand.  The peaks of interest are 
associated with the C-N stretching mode in 2,2’-bipyridyl, 1,10-phenathroline and  
1,10-phenanthroline-5-amine. Table 4.2.1 compares the frequencies of the ν(C-N) stretch of 
the free co-ligand with the co-ligand frequencies after chelation to form the heteroleptic 
complexes. 









Table 4.2.1 highlights an interesting trend for the 2,2’-bipyridyl and 1,10-phenathroline  
co-ligands and their respective copper(II) complexes. The free ligands have medium peaks for 
the C-N stretch in the region of 1500-1600 cm-1. The heteroleptic complexes all showed a 
decrease in frequency for the same bond stretch which is attributed to the electron 
withdrawing nature of the copper(II) metal center. Oxidised metal ions are electron deficient 
and will remove electron density from the ligands which will result in a weakening of the bonds 
Co-ligand Frequency (cm-1) Frequency in heteroleptic 
complex (cm-1) 
 1555 1502 
1577 1526 
 1501 1461 
1586 1507 
 1487 1491 
1454 1461 
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in the region of the coordination sphere. This manifests as a decrease in the frequencies of 
the ν(C-N) stretching mode for the complexes.  
There is a noticeable decrease in the ν(C-N) frequency for 1,10-phenanthroline-5-amine 
compared to the 2,2’-bipyridyl and 1,10-phenathroline co-ligands. The ligand is seen to have 
stretching frequencies in the region of 1454 and 1487 cm-1 while the other two ligands have 
shifts at higher frequencies, in the order of 1500 cm-1. This decrease is attributed to the 
electron withdrawing effect of the NH2 group which reduces electron density over the fused 
aromatic rings. This lowers the bond order and leads to lower stretching frequencies. 
Figure 4.2.1 shows an overlay of the IR spectra of the co-ligand 2,2’-bipyridyl with that of the 
heteroleptic copper(II) complex, [Cu(L1)(Bpy)](Cl). The peaks of interest at 1555 and  
1577 cm-1 for 2,2’-bipyridyl are the C=N stretching frequencies. These bands are shifted to 
lower wave numbers (1526 and 1502 cm-1, respectively) once chelated to the copper(II) metal 
center.  Another peak of interest in the chelate spectrum occurs at 1602 cm-1, which is not 
seen in the co-ligand spectrum. This strong peak is caused by the C=N double bond of the 
Schiff base ligand thus confirming the coordination of both ligands to the copper(II) metal 
center. The imine bond stretching frequency of the metal chelate is also noted to be at lower 
wavenumbers for comparable free ligands. In a study by Akerman et. al. three similar free 
ligands were noted to have imine bond stretching frequencies ranging from  
1632.18 cm-1 – 1643.67 cm-1.51  The imine bond stretching frequency of the metal chelate is 
also lower than the literature value of 1680 cm-1 for an uncoordinated bond. This shift to lower 










Figure 4.2.1: IR spectrum overlay of 2,2'-bipyridyl (green) with the corresponding heteroleptic complex [Cu(L1)(Bpy)](Cl)  
(purple).  
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4.3 Nuclear Magnetic Resonance (NMR) Spectroscopy 
4.3.1 Introduction 
NMR spectroscopy is mostly used to identify and confirm the carbon-hydrogen framework of 
organic and inorganic molecules.50 Nuclei of atoms such as 1H, 13C, 15N, 19F and 31P, all possess 
spin, caused by an odd number of protons or neutrons, which are detected by NMR. It is this 
spin property that allows certain atoms to be studied by NMR spectroscopy. Due to the charge 
and spin, these nuclei have magnetic moments. These magnetic moments are randomly 
orientated in the absence of an externally applied magnetic field. However, in the presence of 
a strong magnetic field the magnetic moments align either with (lower energy α-spin state) or 
against (higher energy β-spin state) the applied magnetic field.50 This process is illustrated in 







Figure 4.3.1: Magnetic moment behaviour of nuclei with and without an applied magnetic field.3 
When the nuclei absorb radio frequency radiation, they flip their spin from an α-spin state to  
a β-spin state. When the nuclei flip back down to the lower energy α-spin state, the spin 
flipping of the nuclei generates a signal whose frequency correlates to the energy difference 
between the α and β spin states. The NMR spectrometer detects and analyses these signals 





 β spin state 
α spin state 
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In this study 1H and 13C NMR spectroscopy were used as a characterisation and structural 
elucidation tool for all ligands. The copper(II) chelates could not be studied by NMR 
spectroscopy due to an unpaired electron in the d9 electronic configuration of the copper(II) 
centre, thus making the complexes paramagnetic and NMR inactive. 
4.3.2 Results and Discussion  







Figure 4.3.2: Structure of 1,10-phenanthroline-5-amine showing hydrogen numbering scheme. 
 
1,10-phenanthroline-5-amine is used as a ligand and building block for a further two ligands 
as the amine group is an ideal site for functionalisation. The ligands L3 and L4 containing biotin 
and propionic acid substituents, respectively were synthesised from phen-amine. L3 will be 
used as a representative example for both L3 and L4 in further discussion. Figure 4.3.3 shows 
the 1H NMR spectrum of phen-amine as well as the downfield region of the NMR spectrum of 
L3. 1H and 13C NMR spectra for all ligands are fully assigned in the experimental section 
(Chapter 2). The respective 1H and 13C NMR spectra for each ligand available in Appendix A2. 















Figure 4.3.3: 1H NMR spectra of the aromatic (downfield) region of L3 and phen-amine. 
 
Amine NH chemical shifts can occur anywhere between 1.0 ppm – 6.0 ppm depending on the 
surrounding substituents, concentrations and hydrogen bonding in solution. The 1H NMR 
spectrum for phen-amine shows a very distinctive, singlet amine peak at 6.12 ppm. After the 
coupling of biotin, the NMR spectrum illustrates the disappearance of the amine peak and the 
appearance of an amide peak at 10.13 ppm, which is not present in the phen-amine spectrum. 
Amide chemical shifts are commonly observed between 5.0 ppm – 9.0 ppm and may vary due 
to surrounding atoms. Hydrogen bonding could be attributed to the peak lying slightly outside 
of the designated range for amide chemical shifts. Similar changes indicative of a successful 
coupling reaction and amide bond formation are noted for L4. 
Figure 4.3.4 shows fully assigned 1H NMR spectrum of L3, this is followed by the fully labelled 
13C NMR spectrum of L3 in Figure 4.3.5. Both spectra were assigned using additional structural 
information obtained from the two-dimensional HSQC and COSY NMR experiments.  
PPM 10.2 10.0 9.8 9.6 9.4 9.2 9.0 8.8 8.6 8.4 8.2 8.0 7.8 7.6 7.4 7.2 7.0 6.8 6.6 6.4 6.2 6.0 5.8













































Figure 4.3.5: Fully assigned 13C NMR spectrum of ligand L3.  
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The 13C NMR spectrum highlights the wide range of carbon nuclei found within the ligand. 
Both the 1H and 13C NMR spectra confirm the successful synthesis and purity of ligand L3. The 
biotin portion of the ligand has chemical shifts which occur at lower frequencies between  
1.20 ppm – 4.40 ppm in the 1H NMR spectrum. The region of 1.20 to 2.40 ppm of the 1H NMR 
spectrum of L3 is dominated by multiplet signals. These are ascribed to the numerous alkyl 
protons. These protons are present upfield due to the electron dense environments which 
shield the protons, resulting in a reduced effective magnetic field. 
4.4 Uv/visible Spectroscopy 
4.4.1 Introduction 
UV/vis spectroscopy provides valuable information for compounds that have conjugated π 
systems. UV light has wavelengths ranging from 180 – 400 nm while visible light has 
wavelengths ranging from 380-780 nm. Both UV and visible light have sufficient energy to 
cause electronic transitions, promoting electrons from lower energy molecular orbitals (MOs) 
to higher energy MOs. The presence of electrons in the lowest energy MOs is referred to as 
the ground state electronic configuration. When a molecule absorbs light with an appropriate 
amount of energy, an electron is promoted to a higher energy MO. The molecule is now in the 
excited state. The absorption is detected and a spectrum is produced. Figure 4.4.1 shows the 









Figure 4.4.1: Relative energies of antibonding, bonding and non-bonding molecular orbitals showing possible electronic 
transitions.  
 
σ* antibonding MO 
π* antibonding MO 
nonbonding MO 
π bonding MO 






π → π* transition 
n → π* transition 
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Only two electronic transitions are commonly observed in UV/vis spectroscopy as shown in 
Figure 4.4.1. A non-bonding electron (n) promoted into a π* antibonding MO is an electronic 
transition requiring a lower energy photon (n → π* transition). An electron promoted from a 
π bonding MO into a π* antibonding MO is an electronic transition of higher energy  
(π → π* transition). Therefore only compounds that contain π electrons can absorb UV/visible 
radiation, generating a spectrum. In general the molar absorptivity of n-π* transitions is 
significantly lower than that of π-π* transitions. 
Using the Beer-Lambert Law, A = εcl, the molar absorptivity or molar extinction coefficient (ε) 
of a compound can be determined from a plot of absorbance versus concentration. The molar 
absorptivity is a constant that is characteristic of a compound at a given wavelength. 
 
4.4.2 Results and Discussion 
Absorption spectroscopy was used to investigate the electronic structure of all complexes 
within this study. UV/vis spectra for all complexes are available in Appendix A-3. The complex 
[Cu(L1)(Cl)] exhibits a high intensity peak at 228 nm which is attributed to a π → π* transition 
(refer to Figure 4.4.2). The less intense peak at 420 nm is a metal-to-ligand charge transfer 
(MLCT) band. A superposition plot with [Cu(L1)(Phen-NH2)](Cl), shows the same high intensity 
peak at 226 nm; similarly the result of π→π*transitions. However, at 287 nm an additional 
peak is noted as a result of π → π* transition centered on the co-ligand 1,10-phenanthroline-
5-amine. The MLCT transition at approximately 420 nm is largely unchanged in both spectra, 


























Figure 4.4.2: Overlay of the UV/visible spectra of [Cu(L1)(Cl)] (green) and [Cu(L1)(phen-NH2)](Cl) (purple) highlighting the 
additional peak at 282 nm as a result of the phen-amine co-ligand. The peak at 228 nm is attributed to the 
Schiff base ligand. 
An offset plot of [Cu(L1)(Cl)], [Cu(L1)(Bpy)](Cl) and [Cu(L1)(Phen)](Cl) illustrates that as the 
conjugation increases by adding the co-ligand 2,2’-bipyridyl to [Cu(L1)(Cl)], the spectra gains 
a π → π* transition band between 260 - 300 nm. Substituting 2,2’-bipyridyl with  
1,10-phenanthroline, shows that as conjugation of the co-ligand increases, an additional 
 π → π* transition between 240 -280 nm is observed. The MLCT band at approximately  
420 nm is ubiquitous confirming that that the copper(II) metal centre is present in all cases 









Figure 4.4.3: Offset overlay of [Cu(L1)(Cl)] (blue), [Cu(L1)(Bpy)](Cl) (green) and [Cu(L1)(Phen)](Cl) (purple) highlighting the 
influence of increased conjugation of the co-ligand on the UV-visible spectra. 
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Table 4.4.1 summarises the extinction coefficients at the corresponding wavelengths (λmax) for 
the absorption bands for all copper(II) metal chelates reported in this study. 
Table 4.4.1: A summary of the wavelengths (λmax) and extinction coefficient (ε) for the copper(II) complexes.  
Complex λmax / nm 
ε / M-1 cm-1 
λmax / nm 
ε / M-1 cm1 
λmax / nm 
ε / M-1 cm-1 
λmax / nm 
ε / M-1 cm-1 
[Cu(L)(Cl)2] 273 
14 026 








































4.5 DNA Binding Studies 
4.5.1 Introduction 
Deoxyribonucleic acid (DNA) is a crucial genetic biomolecule which encompasses all genetic 
information for the development and functioning of living organisms. Its ability to carry 
hereditary information as well as aid in the synthesis of enzymes and proteins highlights its 
significance as a biomolecule. It thus has become a vital cellular target for antiviral, 
antibacterial and anti-cancer drugs.52 The interaction of transition metals such as copper with 
DNA have been under investigation for decades acting as structural probes and 
chemotherapeutic agents.53 The copper(II) complexes in this study are predicted to exert their 
cytotoxicity through DNA binding and hydroxyl radical-induced DNA cleavage. Previous 
research suggests that this class of complexes bind to the DNA via two distinctive modes. 
Firstly, by hydrophobic interactions in DNA’s minor groove followed by partial intercalation of 
the co-ligand into the major groove.22  
DNA interactions with drugs have been investigated widely through numerous techniques 
such as DNA melting curves, viscosity measurements, gel electrophoresis, molecular docking, 
UV/vis spectroscopic methods and fluorescence measurements.54 In this study, the technique 
of fluorescence competitive DNA binding titrations was used to determine the apparent 
binding affinity of the copper(II) complexes to calf thymus DNA (ctDNA). 
Page | 58  
 
Ethidium bromide (EB) is a planar, aromatic dye which readily intercalates between the base 
pairs of ctDNA. It is used as a fluorescent probe to investigate the competitive binding 
properties of other compounds with ctDNA. EB and ctDNA both have weak fluorescence 
properties, however, once the EB has intercalated the DNA the EB-ctDNA complex produces 
strong fluorescence emission. The conjugate exhibits an intense peak at approximately  
614 nm in the emission spectrum after excitation at 500 nm. The increased emission intensity 
of the EB/DNA conjugate compared to either free species is attributed to two factors. Firstly, 
ctDNA’s nucleic acids absorb UV light at 260 nm and then transfer this energy to EB. Secondly, 
when intercalated EB absorbs energy in the range of 300-360 nm. This energy excites EB to 
emit fluorescence with a wavelength of 587 nm.54 The addition of a second DNA intercalator 
(in this case the copper(II) chelate) will quench the fluorescence emission of EB/ctDNA 
conjugate by replacing the EB in the double helix of the DNA molecule. 
 
In the course of the DNA titrations, the EB is displaced by the copper(II) chelate. Therefore, 
the binding affinity of the EB must be determined to calculate the binding constant of the 
metal complex. The binding constant of the EB is determined via direct UV/vis spectroscopic 
titrations which involve monitoring the decrease in absorption of EB in solution as a function 
of ctDNA concentration. A decrease in the intensity of the EB absorption band in the  
650-350 nm region is indicative of DNA intercalation as the intercalation reduces the effective 
concentration of the EB, reducing the absorbance. Compounds with an apparent binding 




The ctDNA utilised for both the direct and competitive DNA binding studies was purchased 
from Sigma Aldrich as the highly polymerised sodium salt and was used to prepare a ctDNA 
stock solution in 25 mM Tris-HCl buffer. The buffer was prepared with ultrapure water  
(resistivity = 18 M) and adjusted to a pH of 7.0 using 1 M HCl. The exact concentration of the 
ctDNA stock solution was determined using the Beer-Lambert law by measuring the 
absorption at 260 nm and using the extinction coefficient of 13 200 M-1 cm-1. 
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The EB stock solution used in the DNA titrations had a concentration of 9.60 × 10-5 M in TrisHCl 
buffer (pH 7.0) solution at 25 oC in a 1.0 cm path length quartz cuvette. The ctDNA stock 
solution (2.79 × 10-3 M concentration) was added to the EB solution in small aliquots followed 
by a ten minute incubation period after each addition.  This incubation period was to ensure 
that the intercalation process was complete and equilibrium was established before the 
spectra were recorded. The absorption spectra were recorded in the range 800-200 nm.55 The 
following equation was used to determine the DNA binding constant of EB: 
Equation 4.5.1: 
(
𝜀𝑎 −  𝜀𝑓
𝜀𝑏 −  𝜀𝑓














a  = Extinction coefficient of EB band at given [ctDNA]  
f  = Extinction coefficient of free EB 
b  = Extinction coefficient of fully intercalated EB 
Kb  = Equilibrium constant in M-1 
Ct  = Total Concentration of ctDNA 
s   = Binding site size (number of nucleotides per EB) 
 
The competitive binding studies to determine the binding affinities of the metal chelates were 
performed as follows. Aliquots of copper(II) chelate stock solutions (concentration range 
1.42 – 1.90 mM dissolved in ultra pure water) were added  to a solution containing 15 µM 
ctDNA and 15 µM EB in 25 mM Tris-HCl Buffer at ten minute intervals and the solution 
emission spectra were then recorded. The samples were excited at 500 nm and the emission 
was recorded between 530 and 800 nm. The apparent binding constant, Kapp, for each metal 
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Equation 4.5.2: 
Kapp[Complex] = KEB[EB] 
Where: 
KEB   = ctDNA binding constant of EB 
[EB]  = EB  molar concentration  
[Complex] = Concentration of the chelate that caused a 50% reduction in the initial   
                             fluorescence intensity 
The quenching of the EB-ctDNA fluorescence can be confirmed by a plot fitted with the linear 
Stern-Volmer equation: 
Equation 4.5.3: 
𝐼0 𝐼 = 1 + 𝑘𝑟⁄  
Where: 
Io  = Emission intensity of EB-ctDNA complex 
I  = Emission intensity of the quenched EB-ctDNA complex 
r   = ratio of total concentration of metal chelate to DNA concentration 
k   = Stern Volmer constant 
 
4.5.3 Results and Discussion 
Competitive DNA binding studies were carried out on ctDNA by varying the concentrations of 
the copper(II) chelates and monitoring the impact on emission intensity. The enhanced 
fluorescence of the EB-ctDNA complex is quenched by the addition of the metal chelate which 
replaces the EB, thus causing a diminishing emission intensity of the solution. All six complexes 
within this study showed the characteristic quenching of the EB-ctDNA solution; indicative of 
DNA binding. As a representative example, [Cu(L1)(Phen-NH2)](Cl) will be discussed in detail. 
The emission spectra as well as the Stern-Volmer plots of the remaining complexes are 
available in Appendix A-4.  
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To calculate Kapp from Equation 4.5.2, the binding constant of EB (KEB) to ctDNA is required. 
This was determined in an independent study by performing a direct DNA titration with EB 
and ctDNA. EB’s decreasing absorbance (hypochroism) as well as the bathochromic shift of 
the absorption band with increasing concentration of ctDNA is indicative of intercalation 






Figure 4.5.1: (Left) Absorption spectra of EB in the presence of increasing concentrations of ctDNA. (Right) Non-linear fit of 
EB titration with ctDNA at 480 nm to determine KEB.  
The absorption spectra in Figure 4.5.1 illustrate the hypochromic and the bathochromic shifts 
which are characteristic of the DNA intercalation process.55 The ethidium bromide binding 
constant (KEB) was determined using Equation 4.5.4 to be 7.74 × 105 M-1.The fluorescence 
quenching of the EB/ctDNA conjugate by the metal chelates confirm that the metal chelates 
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Figure 4.5.2 shows that the copper(II) complexes compete with EB for binding sites on the 
ctDNA helix and displace the strongly intercalated EB; this proves DNA binding. Equation 4.5.2 
was used to determine the apparent binding constant (Kapp) for each of the metal chelates. 
The complex concentration (3.38 × 10-5 M) at which a 50% reduction of the fluorescence 
intensity of EB occurred was determined by a non-linear fit of the change in emission intensity 
at 611 nm as a function of increasing chelate concentration.  Figure 4.5.3 shows both the non-
linear as well as the Stern-Volmer plots. 
 
Figure 4.5.3: (Left) Least-squares fit of the emission intensity at 611 nm with increasing metal chelate concentration. 
(Right) Stern-Volmer plot for [Cu(L1)(Phen-NH2)](Cl). 
 
The Kapp values for the remaining metal chelates are summarised in Table 4.5.1. EB is 
considered to be a strong DNA intercalator (binding constant of 7.74 × 105 M-1) and a 
comparison of the copper(II) chelates with EB, suggests that the chelates presented in this 
study have a similarly high ctDNA binding affinity. 
Table 4.5.1: Summary of Kapp values for the copper(II) chelates determined by competitive DNA binding studies.  
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The data in Table 4.5.1 clearly show there is a relationship between the structure of the 
copper(II) chelates and their DNA binding affinity. [Cu(L1)(Cl)] has the highest apparent 
binding constant due to the planar nature of the complex, aiding in it’s ability to bind to the 
ctDNA. This complex is used as the building block in the heteroleptic complexes; its high 
binding affinity shows that it is an ideal choice for this purpose. A decrease in binding 
constants is noted for the three heteroleptic complexes [Cu(L1)(Bpy)](Cl), [Cu(L1)(Phen)](Cl) 
and [Cu(L1)(Phen-NH2)](Cl) as was expected, due to the added co-ligand hindering the 
intercalation process. Even though a decrease in the binding affinity is observed, the binding 
constants are still of the same order of magnitude as EB; an encouraging result. 
Taking a closer look at only the three heteroleptic complexes, predicted binding patterns were 
confirmed. As the ring number on the co-ligand increases from [Cu(L1)(Bpy)](Cl) to 
[Cu(L1)(Phen)](Cl), an increase in the DNA binding constant is observed. The greater the 
extended aromaticity, the more efficiently a complex is able to interact with the aromatic base 
pairs of the DNA helix. Additional aromaticity leads to favourable π···π interactions between 
the chelates and the aromatic DNA base pairs. These attractive forces increase the stability of 
the DNA/drug conjugate which manifests as a higher DNA binding constant. 
The binding constants of both phenanthroline-based complexes are comparable, suggesting 
that the added NH2 group has no significant role in DNA interactions. This is an unexpected 
result as the hydrogen bonding ability of the NH2 group is expected to further stabilise the 
DNA/drug conjugate. [Cu(L2)(Cl2)] and [Cu(L)(Cl2)] contain N,N’N’’ donor atom sets and 
possess the lowest binding constants. X-ray crystallography of [Cu(L2)(Cl2)] (vida infra) shows 
the complex to be in a square pyramidal geometry with one chloride ion approximately 
perpendicular to the rest of the complex. The position of this chloride ion diminishes the 
planarity of the complex thus decreasing its ability to effectively interact with the DNA helix. 
As it has been shown that the planarity of the co-ligands has an influence on the DNA binding 
affinity, increasing this factor could have favourable results. This could be achieved using 
ligands such as DPQ and DPPZ. It is also important to note that DNA binding is more complex 
than mere planarity of the complexes. The majority of the chelates developed in this study 
carry an overall positive charge. This serves to stabilise the DNA/drug conjugate through 
favourable electrostatic interactions with the negatively charged phosphate backbone of the 
DNA helix. The lipophilicity of the complex can also play a role in DNA binding as more 
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lipophilic complexes interact more strongly with the lipophilic core of the DNA helix.40 This 
could explain why the more polar [Cu(L1)(Phen-NH2)](Cl) complex had a lower binding affinity 
than  [Cu(L1)(Phen)](Cl).    
Table 4.5.2 summarises the Kapp values of comparable previously reported copper(II) chelates. 
Table 4.5.2: Structures and Kapp values of previously reported copper(II) chelates and complexes of this study. 
Complexes from literature Kapp  (M-1) Complexes from this study Kapp  (M-1) 
 
Ganeshpandian, et al.39 
 
 






Ravichandran, et al.38 
 
 





Rajarajeswari, et al.56 
 
 





Qiao, et al.36 
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Table 5.4.2 continued… 
 






















There are a number of structural similarities between the copper(II) chelates in Table 4.5.2 
and those in this work. Firstly, the donor atoms are either N,N’,N’’ or N,N’,O and secondly, 
similar co-ligands were used. The copper(II) chelates in the studies of Ganeshpandian, et al.39, 
Ravichandran, et al.38 and Rajarajeswari, et al.56 have 1,10-phenanthroline-based co-ligands 
and the Kapp values are lower than that of [Cu(L1)(Phen)](Cl). The copper(II) chelate by Qiao, 
et al.36 contains N,N',O donor atoms, is a single-ligand chelate and is comparable to 
[Cu(L1)(Cl)]. The Kapp of 6.40 × 105 M-1 is comparable, though slightly lower, than that of 
[Cu(L1)(Cl)] which was measured to be 8.65 × 105 M-1. The copper(II) chelates by Rajendiran, 
et al.57  and Jaividhya, et al.58 have DPQ and DPPZ co-ligands, respectively. These copper(II) 
chelates have high binding affinities compared to the other reported structures and those of 
this work. Increasing the aromaticity of the co-ligand seemingly plays a significant role in the 
interactions with the DNA helix leading to increased binding affinities. The table highlights that 
varying the donor atoms and changing the co-ligand can have a significant influence on the 
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interactions of the chelates with DNA. The link between ctDNA binding constants and 
cytotoxicity will be explored in Chapter 6.  
4.6 Hydroxyl Radical Assay 
4.6.1 Introduction 
One of the key attributes of copper toxicity comes from its ability to participate in oxidation 
and reduction reactions and therefore catalyse the formation of reactive oxygen species (ROS) 
in a biological environment. In the presence of reducing agents, such as ascorbic acid, Cu2+ is 
reduced to Cu+ which can generate hydroxyl radicals from hydrogen peroxide via the Haber-
Weiss reaction.59 Scheme 4.6.1 shows the production of hydroxyl radicals catalysed by 
copper(II) which induce DNA cleavage. 
 
HS-R-S- + Cu2+ → HS-R-S· + Cu+ 
HS-R-S· + O2 → S-S-R + H+ + O2-. 
2O2-. + 2H+ → H2O2 + O2 
Cu+ + H2O2 → OH· + OH- + Cu2+ 
OH· + DNA → Fragments 
 
Scheme 4.6.1: The reaction equations for the formation of hydroxyl radicals for DNA degradation catalysed by copper(II). 
 
Hydroxyl radicals are one of the most powerful oxidising agents found in biological systems. 
Oxidative damage can occur when OH⋅ abstracts an electron from an amino-bearing carbon, 
producing a carbon-centered protein radical or from unsaturated fatty acids to form a lipid 
radical. The electron deficient radicals can also attack the aromatic DNA base pairs, inducing 
single and double-stranded DNA cleavage.59 The process for the generation of ROS leading to 
DNA cleavage is depicted in Figure 1.3.2 in the introduction. 
 
To investigate this process, hydroxyl radical assays were carried out using Rhodamine B dye 
(Figure 4.6.1) which acts as spectrophotometric indicator. Rhodamine B is highly conjugated 
with four N-ethyl groups at either side of the xanthene ring system. As the electron deficient 
radicals are produced, they attack the electron-rich π-system of the dye causing degradation. 
The loss of extended conjugation in the dye leads to a decrease in the intensity of the 
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absorption of rhodamine B. Rhodamine B therefore acts as an analogue of the electron-rich 










Figure 4.6.1: Chemical structure of Rhodamine B dye.15  
 
4.6.2 Experimental 
To generate the hydroxyl radicals a number of cellular reagents are required; Table 4.6.1 
shows the required stock solutions with the respective concentrations used in the hydroxyl 
radical assay. Sodium ascorbate is used to represent the thiols present in the human body. 
Hydrogen peroxide is also present in cells as a result of various cellular processes.61 
Table 4.6.1: Concentrations of stock solutions used for the hydroxyl radical assay.  
Stock solution Concentration (M) 
Rhodamine B 3.60 × 10-5 
Metal Chelate 1.44 – 1.89 × 10-3 
Hydrogen peroxide 2.70 × 10-2 
Sodium ascorbate 2.61 × 10-3 
 
4.6.3 Results and Discussion 
A hydroxyl radical assay was conducted on all copper(II) chelates to determine whether the 
complexes can generate hydroxyl radicals (which have the ability to damage DNA) under 
pseudo cellular conditions. The graph in Figure 4.6.2 illustrates the kinetic traces for 
[Cu(L1)(Bpy)](Cl) along with a control run using distilled water. This is a representative 
example of the bulk of the metal chelates. The control run was used to prove that in the 
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absence of a copper(II) chelate, the reagents alone do not produce hydroxyl radicals. This was 
confirmed by the kinetic graph for water which remains constant throughout the kinetic scan. 
 
Figure 4.6.2: Kinetic curve of [Cu(L1)(Bpy)](Cl) illustraing the decrease in absorbance of rhodamine B at 553 nm. This 
decrease in absorbance is a result of degradation of the dye by hydroxyl radicals. 
All six metal chelates showed a similar decreasing absorbance at 553 nm, indicative of the 
production of hydroxyl radicals and decay of the dye. This assay confirms that the copper(II) 
chelates catalyse the production of hydroxyl radicals. This same process is likely a vital step in 



















Page | 69  
 
Chapter 5 | X-Ray Crystallography  
5.1 Introduction 
5.1.1 General 
Single crystal X-ray diffraction experiments were utilised to investigate the solid state 
structures of the copper(II) chelates synthesised in this study. These experiments will provide 
valuable information on the solid state interactions of the chelates and contribute to the 
current body of knowledge regarding single-ligand and heteroleptic copper(II) chelate crystal 
data. A survey of the Cambridge Structural Database62 (CSD) showed X-ray structures of similar 
chelates to those presented in this work. These will be briefly reviewed as an introduction to 
this chapter followed by a discussion of the experimental X-ray data obtained in this study. 
5.1.2 Previously reported Schiff base ligand  
Condensation of 8-aminoquinoline with salicylaldehyde affords  
2-N-(quinoline-8-yl)iminomethylphenol (HL1) which is the N,N’,O Schiff base ligand used as 
the primary ligand in the heteroleptic complexes in this work. HL1 has been previously 
synthesised, characterised and coordinated to a range of various transition metals including 
zinc, cobalt, iron and silicon.63, 64, 65, 66 A search of the CSD showed the crystal structure of the 
free ligand has been elucidated. NEZQAL (CSD Reference code for ligand structure) contains 
four molecules is the unit cell and crystallises in the monoclinic space group P21/n. The 








Figure 5.1: Partially labelled X-ray crystal structure of NEZQAL.66 
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The structure of NEZQAL shows that the quinoline heterocyclic ring system is almost coplanar 
with the π-ring system of the salicylideneimine moiety (the salicylic ring system including the 
imine bond). The angle between the two mean planes measures 3.81(1)°. Figure 5.2 shows 











Figure 5.2: Mean planes of the quinoxaline and salicylide moieties showing the almost coplanar nature of the ligand 
NEZQAL. The quinoline ring system lies in the purple plane, while the salicylic ring system lies in the green 
plane.66 
NEZQAL exhibits a bifurcated intramolecular hydrogen bond with the phenolic OH acting as a 
hydrogen bond donor to both the imine and quinoxaline nitrogen atoms (hydrogen bond 
acceptors).66 This is shown in Figure 5.3 (a) below. The hydrogen bond parameters are 
summarised in Table 5.1. The lattice is stabilised by π···π interactions between the aromatic 
phenol and quinoxaline moieties of adjacent molecules. This leads to a one-dimensional 









Figure 5.3:  (a) Bifurcated hydrogen bonding exhibited by NEZQAL in the solid state. (b) One-dimensional π-stacked 
columns of NEZQAL viewed down the a-axis.66  
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Table 5.1: Hydrogen bond parameters (Å, °) of NEZQAL.66 
Hydrogen Bond D–H H∙∙∙A D∙∙∙A D–H∙∙∙A 
O–H∙∙∙Nimine 1.01(2) 1.59(2) 2.526(2) 152(1) 
O–H∙∙∙Nquinoxaline 1.01(2) 2.59(2) 3.356(2) 133(1) 
 
The π-stacked columns are cross-linked by weak C–H···π interactions. This leads to a 
herringbone pattern in the crystal lattice. This packing pattern is illustrated in Figure 5.4. 
 
Figure 5.4: Herringbone pattern of NEZQAL viewed down the a-axis. This supramolecular structure is stabilised by both 
π∙∙∙π interactions and C–H∙∙∙π interactions.66 
 
5.1.3 Previously reported copper chelates 
In this study a total of six copper(II) metal chelates were synthesised, of which three were 
heteroleptic and three were single-ligand complexes. From the synthesised complexes, six 
crystal structures were obtained encompassing five of the metal chelates. One complex, 
[Cu(L2)(Cl)2], was isolated as two pseudo-polymorph crystals. A search of the CSD62 showed 
numerous metal chelates which are structurally comparable to those of this study. A selection 
of the most pertinent structures will be discussed within this chapter. Table 5.2 provides a 
summary of relevant metal chelates followed by Figure 5.5 which shows the structures of the 
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Table 5.2: Previously reported X-ray crystal structures of relevant metal chelates. 
CSD Ref. Code Compound Name Lit. Reference 























Figure 5.5: X-ray crystal structures of (a) CIMMOB67, (b) CIMMUH67, (c) MEHGAJ68 and (d) QITROB69.  
 
The chelates CIMMOB67 and CIMMUH67 both comprise derivatives of ligand L1 with methyl 
and isopropyl substituents, respectively. The ligands have been coordinated to nickel(II) 
chloride; both chelates display a distorted trigonal-bipyramidal geometries. MEHGAJ68 
contains a titanium metal centre bonded to the tridentate ligand (a derivative of HL1) through 
two neutral nitrogen atoms and an anionic phenolic oxygen atom. The remaining three 
coordination sites are occupied by chloride ligands resulting in distorted octahedral geometry. 
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QITROB69 is coordinated to zinc(II) and displays a square-pyramidal geometry. The ligand of 
QITROB is structurally similar the single-ligand chelate [Cu(L)(Cl)2] of this work. 
The average bond lengths and angles for these reported complexes are given in Table 5.3 
where the letter ‘M’ represents the different metal centres for the reported complexes. As 
expected, all bond lengths are comparable with only a slight deviation in the C=Nimine bond 
length of QITROB, which is slightly longer than the rest. Bond angles also lie within a 
reasonable range of each other. However, the bond angle for N2-M-O1 of MEHGAJ is larger 
than the corresponding N2-M-N3 angle of the other three reported structures. This can be 
attributed to the latter forming a six-membered chelation ring as opposed to the five 
membered rings formed in the former. 
Table 5.3: Average bond lengths and bond angles for previously reported metal chelates where M represents metal centre. 
 CIMMOB CIMMUH MEHGAJ QITROB 
Bond Length (Å) 
N1 - M 2.110(4) 2.147(2) 2.191(5) 2.116(2) 
N2 - M 1.982(3) 2.000(3) 2.168(5) 2.085(3) 
N3 - M 2.132(4) 2.167(3) - 2.108(2) 
C = Nimine 1.274(5) 1.279(4) 1.300(8) 1.366(3) 
O1 - M - - 1.797(4) - 
Bond Angles (°) 
N1 - M - N2  79.7(1) 79.0(1) 74.6(2) 76.93(7) 
N2 - M - N3 78.5(1) 78.4(1) - 77.16(8) 
N2 - M - O1 - - 84.1(2) - 
 
A wide range of heteroleptic metal chelates with either the same or slight variations in the  
co-ligands have also been reported. The most relevant structures will be further discussed in 
detail. A common characteristic in the following structures is the N,N',O donor atoms on the 
primary ligand which is in keeping with the heteroleptic complexes of this study. Variations of 
the structures in Figure 5.6 include functionalisation of the primary ligands containing N,N',O 
donor atoms, as well as an increase in the number of rings of the co-ligands.  Table 5.4 provides 
a summary of the relevant chelates.  
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Table 5.4: Reported X-ray structures of most relevant copper(II) chelates. 



































Closely related copper chelates such as DAYMUN70, DAYNAU70, KUPDEF71, QEFCOV73 and 
QEFCUB73 all contain N,N',O donor atoms, with similar co-ligands to those of this study. These 
complexes, however, display variation in the geometry around the metal centre. Figure 5.6 
show the solid state structures for the closely related copper chelates.  
  











Figure 5.6: X-ray crystal structures of the heteroleptic copper(II) chelates(a) DAYMUN70, (b) DAYNAU70 (c) KUPDEF71, (d) 
QEFCOV73 and (e) QEFCUB73. 
The coordination geometry around the copper centres of both DAYMUN and DAYNAU can be 
described as a distorted octahedron while KUPDEF exhibits a square pyramidal geometry. 
QEFCOV and QEFCUB both consist a penta-coordinated complex, similarly displaying a 
distorted square pyramidal geometry. 
Looking more closely at DAYMUN and DAYNAU, each complex shows a single neutral 
tridentate ligand which is coordinated meridonial with the remaining three coordination sites 
occupied by a bidentate ligand (Phen and Bpy, respectively) and a monodentate aqua ligand. 
The Cu-N bond distances in DAYMUN (average 2.0976 Å) lie within good correlation with the 
Cu-N distances for other closely related copper(II) complexes.70, 74 Conventional hydrogen 
bonding is observed for these structures where O-H···O and N-H···O intramolecular and 
intermolecular hydrogen bonding stabilise the complex supramolecular structures.70 
The geometry of the metal chelate KUPDEF is square pyramidal with the two DPQ nitrogen 
atoms of the co-ligand positioned respectively at the apex and base of the pyramid. This is 
confirmed by a shorter Cu1-N1 distance (2.028 Å) and a longer Cu1-N4 distance (2.254 Å) 
which is attributed to Jahn-Teller distortion.71 
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The X-ray structures of QEFCOV and QEFCUB display the same structural features as KUPDEF, 
which includes O1, N1 and N2 of the tridentate Schiff base ligand and N3 of the 2,2’-bipyridyl  
co-ligand all occupying the square base of QEFCOV. O1-N1-N2-N3 are observed to be almost 
co-planar with a mean deviation from the square pyramidal base plane of 0.0755 Å for 
QEFCOV and 0.1197 Å for QEFCUB. All Cu-N and Cu-O distances lie within the range of 
previously reported structures.70, 71, 73 A deviation from this is noted with the bond length of 
Cu1-N4 (2.241(2) Å) being longer than the other Cu-N distances. This is due to N4 being the 
axial nitrogen in the square pyramidal geometry.71 
The structures most closely related to those of this study are NOYHAM72, NOYHIU72, 
NOYHOA72 and QEFDAI73, since all contain the primary ligand  
(E)-2-((quinolin-8-ylimino)methyl)phenol, HL1 of this study, with various substituents on the 
salicylaldehyde ring. Additionally, the above mentioned complexes all have bidentate co-
ligands with nitrogen donor atoms such as 2,2'-bipyridine, 1,10-phenanthroline, pyrazino[2,3-
f][1,10]phenanthroline (DPQ) and dipyrido[3,2-a:2',3'-c]phenazine (DPPZ). 
 
Figure 5.7: X-ray crystal structures of (a) NOYHAM72, (b) NOYHIU72, (c) NOYHOA72 and (d) QEFDAI73. The chelates feature 
derivatives of HL1 as their primary ligands and bidentate N-donor co-ligands. 
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All four X-ray structures illustrated in Figure 5.7 are mononuclear chelates with a penta-
coordinated copper(II) centre, each containing one six- and two five-membered chelate rings. 
The copper(II) centre is penta-coordinated by the N,N’,O tridentate primary ligand and two 
nitrogen atoms on the co-ligand. All four chelates also display distorted square pyramidal 
geometry with the tridentate ligand and a single donor atom of the bidentate ligand forming 
the basal plane and the second N-atom of the co-ligand in the axial position. The bond 
parameters describing the coordination sphere of the copper(II) chelates are summarised in 
Table 5.5 and Table 5.6. 
Table 5.5: Average bond lengths (Å) for previously reported copper(II) chelates with square pyramidal coordination 
geometries. 
 NOYHAM72 NOYHIU72 NOYHOA72 QEFDAI73 
N1 – Cu1 1.951(2) 1.948(2) 1.959(2) 1.949(2) 
N2 – Cu1 2.016(2) 2.014(2) 2.010(3) 2.055(2) 
N3 – Cu1 2.031(2) 2.033(2) 2.029(2) 2.027(2) 
N4 – Cu1 2.245(2) 2.261(2) 2.259(3) 2.246(3) 
O1 – Cu1 1.900(2) 1.893(1) 1.913(2) 1.921(2) 
C = Nimine 1.304(3) 1.312(3) 1.297(4) 1.302(3) 
 
Table 5.6: Average bond angles (°) for previously reported copper(II) chelates with square pyramidal coordination 
geometries. 
 NOYHAM72 NOYHIU72 NOYHOA72 QEFDAI73 
N1-Cu1-N2 82.0(1) 82.35(7) 82.8(1) 82.0(1) 
N1-Cu1-O1 93.0(1) 93.36(7) 93.4(1) 93.0(1) 
N3-Cu1-N4 77.1(1) 78.10(7) 78.39(9) 77.1(1) 
N2-Cu1-N3 93.3(1) 96.44(7) 93.7(1) 93.3(1) 
O1-Cu1-N3 91.5(1) 88.20(7) 92.0(1) 91.5(1) 
N1-Cu-N4 103.2(1) 100.66(7) 101.06(9) 103.2(1) 
N2-Cu-N4 96.58(7) 98.60(7) 100.98(1) 93.4(1) 
O1-Cu-N4 100.93(6) 96.59(7) 91.82(9) 99.45(9) 
 
Table 5.5 and Table 5.6 give the average bond lengths and bond angles for the complexes 
NOYHAM, NOYHIU, NOYHOA and QEFDAI. All bond lengths compare favourably with each 
other as expected since all the chelates contain similar N,N’,O tridentate ligands with similar 
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nitrogen donors on the co-ligands. The Cu-N bond distances ranged from 1.948 to 2.055 Å, 
while the Cu-O bond distances range from 1.893 to 1.921 Å. These distances are consistent 
with comparable bond lengths as previously discussed.70, 71 The bond angles also show good 
correlation with each other with slight deviations seen around angles O1-Cu1-N3 and  
N1-Cu1-N4 which are influenced by the angle at which the co-ligand is positioned relative to 
the primary tridentate ligand. The most notable deviation lies in the complex NOYHIU; this is 
attributed to the steric influence of the bulky t-butyl substituents on the tridentate ligand. 
NOYHIU and QEFDAI are used as representative examples to show the angle subtended by the 
co-ligand relative to the primary ligand plane. The mean planes were calculated using all non-
hydrogen atoms in the co-ligands and the aromatic constituents of the tridentate ligands (i.e. 
functional groups were omitted). This information could prove to be a useful indicator to 
determine whether these systems are likely to be effective DNA binding agents. These 









Figure 5.8: The two planes at which the two ligands are positioned to each other for (a) NOYHIU and (b) QEFDAI. The planes 
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Table 5.7: The measured dihedral angle between the mean planes of the primary and co-ligands of the reported copper(II) 
chelates. 











The dihedral angles between the co-ligands and primary ligands for the previously studied 
chelates range from 78.31° – 88.82°. These data show that the two ligands are nominally 
perpendicular. The main factor influencing this parameter is likely to be steric hindrance from 
any bulky substituents on the primary ligands. The chelates will then adopt an orientation 
which will minimise any non-bonded repulsion between these bulky groups and the  
co-ligands. In DNA binding, the angle at which the two planes are positioned is crucial in 
heteroleptic complexes since only one of the two ligands interact directly with the DNA double 
helix. The closer the angle is to 90° the better the intercalation properties.75 
5.1.4 Objectives 
The main objective of the crystallographic studies is to investigate the solid state structures of 
the copper(II) chelates and contribute to the existing body of knowledge relating to 
heteroleptic copper(II) complexes. This study will also provide insight into the nature of the 
solid state interactions that these systems exhibit, providing valuable information as to 
whether these chelates are likely to be effective DNA binding agents. 
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5.2 Experimental  
The X-ray data were recorded on a Bruker Apex Duo diffractometer equipped with an Oxford 
Instruments Cryojet operating at 100(2) K and an Incoatec microsource operating at 30 W 
power. For all structures the data were collected with Mo Kα (λ = 0.71073 Å) radiation at a 
crystal-to-detector distance of 50 mm. The data collections were performed using omega and 
phi scans with exposures taken at 30 W X-ray power and 0.50o frame widths using APEX2.76  
The data were reduced with the program SAINT using outlier rejection, scan speed scaling, as 
well as standard Lorentz and polarisation correction factors.76 A SADABS semi-empirical multi-
scan absorption correction was applied to the data.76 Direct methods, SHELXS and WINGX 
were used to solve all structures.77, 78 All non-hydrogen atoms were located in the difference 
density map and refined anisotropically with SHELXLS.77 The hydrogen atoms of all NH and OH 
groups were located in the difference density map and allowed to refine isotropically. All 
diagrams were rendered using Mercury 3.3.  
The molecular structures were validated using an IUCR checkCIF79 and the reports are 
available in Appendix C.  
Table 5.8 and Table 5.9 provides a summary of the crystallographic data for the single-ligand 
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Table 5.8: Summary of the X-ray data for the single-ligand copper(II) chelates.  
Crystal Data [Cu(L1)(Cl)] [Cu(L2)(Cl)2] [Cu(L2)(Cl)2]·MeOH 
Chemical formula C16H11ClCuN2O·CH3OH C15H11Cl2CuN3 C16H15Cl2CuN3O 
Mr 378.30 367.71 399.75 
Crystal system Triclinic Triclinic Monoclinic  
Space group P-1 P-1 P21/c 
Temperature / K 100 
a / Å 7.9838(4) 6.9474(5) 9.5526(9) 
b / Å 8.8753(5) 8.3637(6) 8.7837(9) 
c / Å 11.7868(6) 12.4235(8) 18.959(2) 
α / ° 71.550(2) 98.995(3) 90.00 
β / ° 71.550(2) 100.072(3) 95.786(5) 
γ / ° 67.783(2) 92.536(3) 90.00 
Z  2 2 4 
Radiation type Mo Kα 
V (Å3) 730.28(7) 700.11(8) 1582.7 
F(000) 386 370 812 
µ (mm-1) 1.69 1.94 1.72 
Crystal size (mm) 0.18 x 0.12 x 0.07 0.26 × 0.09 × 0.05 0.55 × 0.21 × 0.16 
Diffractometer Bruker APEX-II CCD 
Absorption correction Multi-scan SADABS, Bruker 2012 
No. of measured, 
independent and 
observed [I > 2σ(I)] 
reflections  
 
20960, 3285, 3018 
 
11495, 2691, 2553 
 
11341, 3093, 2890 
Rint 0.024 0.016 0.023 
Refinement    
R[F2 > 2σ(F2)], wR(F2), S 0.041, 0.119, 1.13 0.021, 0.055, 1.11 0.025, 0.061, 1.03 
No. of reflections 3285 2691 3093 
No. of parameters 210 190 212 
No. of restraints 0 0 0 
Δρmax, Δρmin (e Å−3) 0.75, −1.59 0.47, −0.23 0.36, −0.35 
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Table 5.9: Summary of the X-ray data for the heteroleptic copper(II) chelates.  
Crystal Data [Cu(L1)(Bpy)](Cl) [Cu(L1)(Phen)](Cl) [Cu(L1)(Phen-NH2)](Cl) 
Chemical formula C26H19Cl1Cu1N4O1 C28H19ClCuN4O2·5H2O C28H20ClCuN5O 
Mr 502.44 535.47 541.48 
Crystal system Monoclinic  Triclinic  Triclinic 
Space group P21/n P-1 P-1 
Temperature / K 100 
a / Å 12.4998(12)  14.0251(11) 10.7071(4) 
b / Å 22.288(2) 14.3232(12) 11.3941(4) 
c / Å 19.0810(16) 14.7635(11) 12.4902(5) 
α / ° 90.00 94.455(4) 106.702(2) 
β / ° 103.856(3) 105.789(4) 109.913(2) 
γ / ° 90.00 114.679(4) 103.598(2) 
Z  8 4 2 
Radiation type Mo Kα 
V (Å3) 5161.1(8) 2530.4(3) 1274.97(9) 
F(000) 2056 1096 554 
µ (mm−1) 0.97 1.00 0.99 
Crystal size (mm) 0.26 x 0.18 x 0.12 0.31 × 0.13 × 0.08 0.05 × 0.03 × 0.02 
Diffractometer Bruker APEX-II CCD 
Absorption correction Multi-scan SADABS, Bruker 2012 
No. of measured, 
independent and 
observed [I > 2σ(I)] 
reflections  
 
36463, 10106, 8704 
 
40319, 11571, 8396 
 
24236, 6605, 5615 
Rint 0.054 0.064 0.023 
Refinement    
R[F2 > 2σ(F2)], wR(F2), S 0.072, 0.212, 1.11 0.055, 0.163, 1.01 0.033, 0.085, 1.06 
No. of reflections 10106 11571 6605 
No. of parameters 595 648 333 
No. of restraints 0 1 0 
Δρmax, Δρmin (e Å−3) 2.22, −1.75 0.75, −1.16 0.52, −0.28 
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5.3 Results and Discussion 
5.3.1 X-ray crystallography of single-ligand copper(II) complexes 
a) X-ray structure analysis of [Cu(L1)(Cl)] 
 
The copper(II) complex of HL1 crystallised in the triclinic space group P-1, with a single 
molecule in the asymmetric unit (Z = 2). The structure of [Cu(L1)(Cl)] consists of dimeric units 
linked by Cu-Cl-Cu bridges. The asymmetric unit comprises a single square planar copper(II) 
chelate with the tridentate ligand and a chloro ligand occupying the four coordination sites. 
The molecule is an inversion dimer bridged by two chloride ions. The molecule crystallised as 
the methanol monosolvate i.e. one methanol molecule per asymmetric unit. The crystal 
structure for [Cu(L1)(Cl)] has been previously crystalised by Liu et al. in the monoclinic space 
group P2(1)/n and also displayed the same polymeric units linked by single Cu-Cl-Cu bridges.80 
The structure reported herein is therefore a polymorph of that previously reported. The 





Figure 5.9: (a) The asymmetric unit of [Cu(L1)(Cl)] and (b) the inversion dimer of [Cu(L1)(Cl)], with thermal ellipsoids drawn 
at the 50% probability level. Hydrogen atoms have been rendered as spheres of arbitrary radius. Symmetry 
code: -x, -y, -z. 
The dimeric µ-chloro structure of [Cu(L1)(Cl)] exhibits the expected square pyramidal 
geometry as noted with previous heteroleptic complexes of this class.70, 73 Selected bond 
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measures 1.305(5) Å and lies within the range of 1.274(5) - 1.366(3) Å for previously reported 
structures. Bond lengths, Cu1-N1, Cu1-N2 and Cu1-O1 measure 1.973(3), 2.002(3) and 
1.908(3) Å, respectively. Again, comparing favourably to similar previously reported 
complexes.80 
The square pyramidal geometry of the metal centre has a basal plane which consists one 
oxygen atom and two nitrogen atoms from the Schiff base ligand and one chloro ligand. The 
base forms a near ideal least squares plane (N1-N2-Cu1-O1-Cl1) with the largest deviation 
from the mean plane occurring at N1 with a deviation of 0.064 Å. The copper(II) ion is displaced 
by 0.132 Å from the same mean plane towards the apical chloride. The apical Cu-Cl bond is 
significantly longer (2.8151(8) Å) than the Cu-Cl bond of the basal chloride ion (2.2924(9) Å). 
The bond angles, N1-Cu1-N2  and N1-Cu1-O1, measuring 82.3(1)° and 93.7(1)°, respectively 
are comparable to related structures.68 The large difference between the two angles is 
attributed to the differing bite of the ligand chelating atoms; the five-membered ring  
(C1-C2-N2-Cu1-N1) having a smaller angle than the larger six-membered  
(C10-N1-Cu1-O1-C12-C11). The bond angles describing the coordination sphere of [Cu(L1)Cl] 
are summarised in Table 5.10. 










* denotes an inversion symmetry related chloro ligand which occupies the fifth coordination site. 
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The chelate [Cu(L1)Cl] crystallises as the methanol monosolvate. The methanol OH group is 
involved in a bifurcated hydrogen bond (i.e. a single H-bond donor and two H-bond acceptors). 
The methanolic OH is hydrogen-bonded to the chloro ligand and the phenolic oxygen atom. 
This hydrogen bonding motif leads to a four-membered hydrogen-bonded ring.  
The hydrogen bonding is depicted in Figure 5.10 below. The hydrogen bond parameters are 








Figure 5.10: Hydrogen bonding motif of [Cu(L1)Cl] showing the bifurcated nature of the intermolecular interaction.  
Hydrogen bonds are shown as dashed blue lines. 
 
Table 5.11: Hydrogen bond parameters (Å, °) of [Cu(L1)Cl]. 
Hydrogen Bond D–H H∙∙∙A D∙∙∙A D–H∙∙∙A 
O–H∙∙∙O 0.84(2) 2.032(2) 2.788(6) 128(1) 
O–H∙∙∙Cl 0.84(2) 2.813(2) 3.391(7) 149(1) 
 
The data in Table 5.11 show that the hydrogen bond lengths are significantly shorter than the 
sum of the van der Waals radius of the interacting atoms by 0.137 and 0.688 Å, for the  
O–H···O and O–H···Cl interactions, respectively. Although bond length does not necessarily 
correlate linearly with bond strength due to packing constraints in the lattice, these bond 
lengths are significantly shorter than the sum of the van der Waals radii and are therefore 
likely to be moderate to strong interactions.  
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b) X-ray structures of [Cu(L2)(Cl)2] and [Cu(L2)(Cl)2]·MeOH 
 
The copper(II) complex [Cu(L2)(Cl)2] crystallised as pseudopolymorphs. After crystallisation by 
slow liquid diffusion of a methanol solution of the chelate into diethyl ether, inspection of the 
crystals revealed two crystals of different shades of green. Crystallographic studies showed 
that one molecule crystallised as the methanol monosolvate ([Cu(L2)(Cl)2]·MeOH) and the 
other was solvent free. [Cu(L2)(Cl)2] crystalised in the triclinic space group P-1 with 
Z = 2; a single molecule in the asymmetric unit. [Cu(L2)(Cl)2]·MeOH crystalised in the triclinic 
space group P21/c with Z = 4 and one chelate and methanol solvate molecule in the 
















Figure 5.11:  Labelled solid state structures of (a) [Cu(L2)(Cl)2] and (b) [Cu(L2)(Cl)2]·MeOH with thermal ellipsoids drawn 
at the 50% probability level. Hydrogen atoms have been rendered as spheres of arbitrary radius.  
(a) 
(b) 
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Both [Cu(L2)(Cl)2] and [Cu(L2)(Cl)2]·MeOH display the typical distorted square pyramidal 
geometry around the copper(II) centre. The two pseudopolymorphs are structurally identical 
but slight variations in bond lengths and bond angles around the metal centre were noted. 
N3-Cu1 and N2-Cu2 have similar bond lengths and are considerably longer when compared to 
N1-Cu1. The bond length N3-Cu1 in [Cu(L2)(Cl)2] is 2.046(2) Å, while the equivalent bond in 
[Cu(L2)(Cl)2]·MeOH measures 2.027(2) Å. The C=Nimine bond length in both structures are 
comparable measuring 1.282(2) and 1.289(2) Å. The Cu-Cl bond lengths are the longest due 
to the chloride ligands having a large van der Waals radius thus extending the bond lengths. 
The N1-Cu1-N2 bond angles in both structures measure 80.62(6)° while N1-Cu1-N3 measures 
79.27(6)° for [Cu(L2)(Cl)2] and 79.62(6)° for [Cu(L2)(Cl)2]·MeOH. The Cl1-Cu1-Cl2 bond angle is 
the most obtuse in both structures and is caused by steric repulsion between the chloro 
ligands. The most notable difference between the structures [Cu(L2)(Cl)2] and 
[Cu(L2)(Cl)2]·MeOH is the Cl1-Cu-Cl2 bond angle. This difference is attributed to the latter 
structure being involved in hydrogen bonding. The larger bond angle seemingly allows for 
more efficient hydrogen bonding. The bond lengths and bond angles describing the 
coordination sphere of [Cu(L2)(Cl)2] and [Cu(L2)(Cl)2]·MeOH are summarised in Table 5.12. 
 












Bond lengths (Å) 
 [Cu(L2)(Cl)2] [Cu(L2)(Cl)2]·MeOH 
N1-Cu1 1.985(1) 1.989(2) 
N3-Cu1 2.046(2) 2.034(2)  
N2-Cu1 2.042(1) 2.027(2)  
Cl1-Cu1 2.4616(5) 2.2461(5)  
Cl2-Cu1 2.2567(6) 2.5208(6)  
C=Nimine 1.282(2) 1.289(2) 
Bond angles (o) 
 [Cu(L2)(Cl)2] [Cu(L2)(Cl)2]·MeOH 
N1-Cu1-N2 80.62(6) 80.62(6)  
N1-Cu1-N3 79.27(6) 79.62(6)  
N1-Cu1-Cl1 97.42(5) 96.76(5)  
Cl1-Cu1-Cl2 105.26(2) 108.45(2)  
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Along with the variations in the bond lengths and angles between the two pseudopolymorphs, 
the structures also have different space groups with a different number of molecules in each 







Figure 5.12: Packing diagram of [Cu(L2)(Cl)2] viewed down the b-axis.  
 
The packing diagram of [Cu(L2)(Cl)2]·MeOH shows four complex molecules and four methanol 
molecules in the unit cell. Figure 5.13 shows the packing of [Cu(L2)(Cl)2]·MeOH with noticeable 









Figure 5.13:  Packing diagram of [Cu(L2)(Cl)2]·MeOH.  
 
The methanol OH group of [Cu(L2)(Cl)2]·MeOH is involved in hydrogen bonding. The 
methanolic OH is hydrogen-bonded to a single chloro ligand. The hydrogen bonding is 
depicted in Figure 5.14. The hydrogen bond parameters are summarised in Table 5.13.  









Figure 5.14:  Hydrogen bonding of [Cu(L2)(Cl)2]·MeOH showing the nature of the intermolecular interaction. The hydrogen 
bond is shown as a dashed blue line. 
 




The data in Table 5.13 show that it is a very short interaction distance. This coupled with the 













Hydrogen Bond D–H H∙∙∙A D∙∙∙A D–H∙∙∙A 
O–H∙∙∙Cl 0.835(3) 2.349(3) 3.183(2) 176(2) 
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5.3.2 X-ray crystallography of heteroleptic copper(II) complexes 
a) X-ray structure analysis of [Cu(L1)(Bpy)](Cl) 
 
The complex [Cu(L1)(Bpy)](Cl) crystallised in the monoclinic space group P21/n, with two 
molecules in the asymmetric unit and Z = 4. A search of the CSD showed that the solid state 












Figure 5.15:  X-ray crystal structure of [Cu(L1)(Bpy)](Cl) showing a single molecule of the asymmetric unit, and atom 
numbering scheme with thermal ellipsoids drawn at the 50% probability level. Hydrogen atoms are rendered 
as spheres of arbitrary radius. 
 
The two molecules within the asymmetric unit are very similar as illustrated by a least-squares 
fit which gives a root mean square deviation (RMSD) of 1.1484 Å. The two molecules will 
therefore be discussed collectively. [Cu(L1)(Bpy)](Cl) exhibits a distorted square pyramidal 
geometry around the copper(II) centre. The basal plane is made up of two nitrogen atoms and 
one oxygen atom from the Schiff base ligand and one nitrogen atom (N2) from the co-ligand, 
Bpy. The apical coordination site is occupied by a nitrogen atom (N1) from the Bpy co-ligand. 
The base does not form an ideal least squares plane since ring bending is observed between 
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the 8-aminoquinoline moiety and the salicylic ring. The largest deviations from the mean plane 
(all non-H atoms of the Schiff base ligand) are 0.083 and 0.156 Å for C4 and C5, respectively. 
The copper(II) ion is displaced by 0.110 Å from the basal plane towards the apical nitrogen 
atom. 
The solid state structure for [Cu(L1)(Bpy)](Cl) illustrates a mononuclear species with a penta-
coordinated copper(II) centre. Three chelating rings are observed around the metal centre 
with one six- and two five-membered rings. The distances between the Cu1 atom and the 
donor atoms are summarised in Table 5.14. All bond lengths lie within the reported range for 
Cu-O and Cu-N bonds. It is also noted that the apical nitrogen N1 has a longer bond length 
measuring 2.214(4) Å, compared to the three Cu-N bond distances for the atoms in the basal 
plane. 
The key bond angles lie within the chelating rings around the metal centre. Angle N4-Cu1-O1 
measures 93.3(1)° while N3-Cu1-N4 has an acute angle of 82.6(1)°. The large difference is 
attributed to the ring sizes, with the six-membered ring C1-O1-Cu1-N4-C7 possessing the 
larger bond angle as compared to the smaller five-membered ring. The chelating ring of the 
co-ligand has the smallest bond angle of 78.1(1)°; a consequence of the small bite angle. The 
bulk of the bond parameters are summarised in Table 5.14. 
















Cu1-N4  1.954(3) 
Cu1-O1 1.931(2) 
C=Nimine 1.311(5) 
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An interesting aspect of heteroleptic complexes is the angle subtended by the two ligands. As 
previously mentioned, this information will aid in the understanding of whether the complex 









Figure 5.16:  Perspective views of the mean planes (all non-H atoms) generated by the two ligands. The tridentate ligand 
lies in the purple plane and the Bpy co-ligand in the green plane. 
 
Figure 5.16 highlights the near perpendicular position of the Bpy ligand relative to the Schiff 
base ligand, subtending an angle of 89.17°. The two planes lie almost perpendicular to each 
other; this orientation should lead to minimal steric strain. When reviewing previous 
heteroleptic complexes of this class it was observed that by adding bulky substituents onto 
the tridentate ligand, it had a noticeable influence of the angle between the planes.70, 71, 73  
Figure 5.16 (b) also highlights the ring bending of the N,N’,O ligand after it is coordinated to 
the copper(II) centre. Section 5.1.2 reported the free N,N’,O ligand (NEZQAL) which had  a 
slight deviation of 3.81° between the quinoline heterocyclic ring system and the 
salicylideneimine moiety. Once coordinated to the copper(II) centre in [Cu(L1)(Bpy)](Cl), the 
same angle increases to 10.85°. This is illustrated in Figure 5.16 (b) where the salicylic ring 
system lies significantly above the plane.  
[Cu(L1)(Bpy)](Cl) does not display any classical hydrogen bonding, however, the structure does 
exhibit intermolecular C-H···O interactions between the phenolic oxygen (O2) of the N,N’,O 
ligand and the bipyridyl C26-H26 group of an adjacent molecule. This leads to the formation 
of a dimeric supramolecular structure with crystallographically imposed inversion symmetry 
(Figure 5.17). Although C-H···O interactions are generally considered weak intermolecular 
(a) (b) 
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interactions. In this case the D···A distance is 0.260 Å shorter than the sum of the van der 
Waals radii suggesting a stronger interaction. In addition to these interactions, the dimer is 
further stabilised by π···π interactions between the Bpy and Schiff base ligands. The 
interplanar spacing measures 3.28 Å, which is shorter than the interplanar spacing in graphite 







Figure 5.17:  The dimeric supramolecular structure of [Cu(L1)(Bpy)](Cl) supported by C-H···O. Viewed down the b-axis. 
 
b) X-ray structure analysis of [Cu(L1)(Phen)](Cl) 
 
[Cu(L1)(Phen)](Cl) crystallised in the triclinic space group P-1 with two molecules in the 
asymmetric unit (Z = 2). The crystal structure for [Cu(L1)(Phen)](Cl) has been previously 
elucidated by Lin et al. in the monoclinic space group P2(1)/c with Z = 4.72 The structure 









Figure 5.18:  X-ray crystal structure of [Cu(L1)(Phen)](Cl) showing a single molecule of the asymmetric unit and associated 
water molecule and chloride counter ion showing the atom numbering scheme. Thermal ellipsoids drawn at 
the 50% probability level. 
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The solid state structure of [Cu(L1)(Phen)](Cl) displays a mononuclear species with a penta-
coordinated copper(II) centre resulting in three chelating rings, i.e. one six- and two five-
membered chelating rings. The copper(II) centre is penta-coordinated by two nitrogen atoms 
and one oxygen atom from the N,N’,O tridentate Schiff base ligand and by two nitrogen atoms 
from 1,10-phenanthroline. This yields a distorted square pyramidal coordination geometry 
around the copper(II) centre.  
Atoms N1, N2, N4 and O1 form the base which is a near ideal least squares plane with N3 
being the apical atom. The largest deviation from the mean basal plane occurs at C16 with a 
deviation of 0.314 Å. The copper(II) centre also shows a displacement of 0.138 Å from the four 
coordinating atoms of the basal plane towards the apical nitrogen. 
[Cu(L1)(Bpy)](Cl) and [Cu(L1)(Phen)](Cl) show similar trends in Cu-N and Cu-O bond lengths. 
N3, the apical atom, has an elongated bond length of 2.242(3) Å when compared the other 
Cu-N bond lengths which range from 1.950(3) - 2.020(3) Å. All bond lengths compare 
favourably with those previously reported  for similar heteroleptic complexes of this class.72 
The six-membered chelate ring and associated bond angle N1-Cu1-O1 (93.42(1)°) is again 
more obtuse than those of the five-membered chelate rings, N1-Cu1-N2 and N3-Cu1-N4 with 
bond angles measuring 83.05(1)° and 77.52(1)°, respectively. Table 5.15 summarises selected 
bond lengths and bond angles for [Cu(L1)(Phen)](Cl). 















Cu1-N4  2.034(3) 
Cu1-O1 1.911(3) 
C=Nimine 1.287(4) 
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The chelate [Cu(L1)(Phen)](Cl) crystallises as the hemihydrate i.e. a single water molecule 
associated with the two metal chelates in the asymmetric unit. The water molecule bridges a 
single chelate and chloride counter ion to form a hydrogen-bonded trimeric structure. The 
hydrogen bonding motif is depicted in Figure 5.19. The hydrogen bond parameters are 








Figure 5.19:  Hydrogen bonding of [Cu(L1)(Phen)](Cl) showing the bridging water molecule and resulting heterotrimeric 
structure.. Hydrogen bonds are shown as dashed blue lines. 
 




The steric bulk of the water molecules along with the steric bulk of the four chloride ions in 
the unit cell could aid crystallisation by reducing the size of the intermolecular cavities. The 
angle at which the two ligand planes are positioned relative to each other measures 89.75°. 
Figure 5.20 highlights the near perpendicular orientation between the tridentate ligand and 





Hydrogen Bond D–H H∙∙∙A D∙∙∙A D–H∙∙∙A 
O–H∙∙∙O 0.83(3) 1.958(3) 2.785(3) 177(4) 
O–H∙∙∙Cl 0.89(6) 2.396(5) 3.137(2) 140(5) 










Figure 5.20:  Two views of the planes generated by the two ligands of [Cu(L1)(Phen)](Cl). The tridentate ligand plane is 
shown in purple and the Phen co-ligand plane is shown in green. 
 
As seen with [Cu(L1)(Bpy)](Cl), the two ligand planes of [Cu(L1)(Phen)](Cl) lie almost 
perpendicular to each other again leading to minimal steric strain. Figure 5.20 (b) also 
highlights the ring bending noted for the N,N’,O ligand after it is coordinated to the copper(II) 
centre.  The angle deviation between the planes of the quinoline heterocyclic ring system and 
the salicylideneimine moiety are much larger for [Cu(L1)(Phen)](Cl) measuring 18.51°. A 
greater angle than that reported for the free ligand NEZQAL which is 3.81°. 
 
(a) (b) 
Page | 97  
 
b) X-ray structure analysis of [Cu(L1)(Phen-NH2)](Cl) 
 [Cu(L1)(Phen-NH2)](Cl) crystallised in the triclinic space group P-1 with a single molecule in 
the asymmetric unit and Z = 2. A search of the CSD showed that the solid state structure of 













Figure 5.21:  Labelled solid state structure of [Cu(L1)(Phen-NH2)](Cl) showing the atom numbering scheme with thermal 
ellipsoids drawn at the 50% probability level. Hydrogen atoms are rendered as spheres of arbitrary radius.  
 
[Cu(L1)(Phen-NH2)](Cl) exhibits the typical distorted square pyramidal geometry around the 
copper(II) centre with one six- and two five-membered chelating rings. The basal plane 
comprises two nitrogen atoms and one oxygen atom from the Schiff base ligand and one 
nitrogen atom (N3) from the co-ligand, Phen-NH2. The apical coordination site is occupied by 
the second nitrogen atom (N4) of the Phen-NH2 co-ligand. The basal plane shows similar 
characteristics to those previously discussed. In this chelate structure, the largest deviation 
from the basal plane occurs at C4 with a deviation of 0.610 Å. The copper(II) ion is displaced 
from the basal plane towards the apical nitrogen with a deviation of 0.124 Å. 
The solid state structure of [Cu(L1)(Phen-NH2)](Cl) shows a mononuclear species with a penta-
coordinated copper(II) centre. Cu-N and Cu-O bond lengths are consistent with those of this 
study as well as those in literature.71, 73 The distances between the Cu1 ion and the donor 
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atoms are summarised in Table 5.17. It is again noted that the apical nitrogen N4 has a longer 
bond length of 2.241(2) Å, when compared to the other Cu-N bond distances. 
Similar trends to those previously discussed with respect to the bond angles of the 
coordination sphere are again noted. N1-Cu1-O1 bond angle measures 92.89(6)° while  
N1-Cu1-N2 measures 82.95(6)°. The large difference is again attributed to the ring and 
associated bite of the ligands. The chelate ring of the co-ligand has the smallest bond angle of 
all three chelates reported herein, measuring 78.78(6)°. 











[Cu(L1)(Phen-NH2)](Cl) exhibits several short H···Cl contacts to the chloride counter ion, with 
a single anion bridging four molecules. The short contacts between the chloride anion and the 
copper(II) chelate are shown in Figure 5.22. 
 




Cu1-N4  2.241(2) 
Cu1-O1 1.940 (9) 
C=Nimine 1.305(2) 















Figure 5.22: Short contacts between the chloride anion and the surrounding copper(II) chelates in [Cu(L1)(Phen-NH2)](Cl).  
The crystal structure shows seven short contacts between the chloride anion and the 
hydrogen atoms of the amino group, the quinoline heterocyclic ring system, the 
salicylideneimine moiety as well the phenanthroline co-ligand. The short contacts stabilise the 
crystal lattice, ultimately aiding in the crystal growth of the desired chelate. Table 5.18 
provides a summary of the short contact distances for [Cu(L1)(Phen-NH2)](Cl). 
Table 5.18: Summary of the lengths of the short contacts to the chloride anion in [Cu(L1)(Phen-NH2)](Cl).  
 
Short contact Length  
Cl···amino H 2.410(3) 
Cl···quinoline H1 2.699(4) 
Cl···quinoline H2 2.909(6) 
Cl···salicylideneimine H 2.868(3) 
Cl···imine H 2.704(9) 
 
The NH2 group of the co-ligand is hydrogen-bonded to a chloride anion and the phenolic 
oxygen atom of an adjacent molecule. This complementary hydrogen bonding pattern  
(Figure 5.23) leads to a dimeric supramolecular structure with crystallographically imposed 
inversion symmetry. The hydrogen bond parameters are summarised in Table 5.19. 
 
 








Figure 5.23: Dimeric supramolecular structure of [Cu(L1)(Phen-NH2)](Cl) with crystallographically imposed inversion 
symmetry. 
 
Table 5.19: Hydrogen bond parameters (Å, °) of [Cu(L1)(Phen-NH2)](Cl). 
Hydrogen Bond D–H H∙∙∙A D∙∙∙A D–H∙∙∙A 
N5–H102∙∙∙O1 0.97(3) 2.00(3) 2.968(2) 171(3) 
N5–H101∙∙∙Cl1 0.96(3) 2.41(3) 3.332(2) 161(3) 
 
These bond lengths are again shorter than the sum of the van der Waals radii, suggesting 
strong interactions. This is further supported by the bond angles approaching ideality.  
 
As was investigated with the two previous heteroleptic chelates, the angle subtended by the 









Figure 5.24:  Two views of the planes generated by the two ligands for [Cu(L1)(Phen-NH2)](Cl). The tridentate ligand plane 
is shown in purple and the Phen-NH2 co-ligand plane is shown in green. 
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Even though [Cu(L1)(Phen)](Cl) and [Cu(L1)(Phen-NH2)](Cl) are structurally identical, with the 
exception of an additional amino group, the angles between the ligand planes are significantly 
different. The angle between the Schiff base ligand and the Phen-NH2 co-ligand measures 
71.39°, a large deviation from [Cu(L1)(Phen)](Cl) (89.75°) and [Cu(L1)(Bpy)](Cl) (89.17°). It is 
likely that this deviation is to accommodate the lattice-stabilising hydrogen bonding. Another 
interesting difference is the deviation between the quinoline heterocyclic ring system and the 
salicylideneimine moiety measures 4.18°. An angle, much closer to the free ligand (NEZQAL) 
which was 3.81°. It would seem that the perpendicular geometry of the two former complexes 
requires this distortion of the tridentate ligand. 
5.4 Conclusion 
The solid state structures of five copper(II) chelates were determined. The copper(II) chelates 
all exhibited a square pyramidal coordination geometry around the metal centre which is in 
keeping with previously reported chelates of this class. The bond lengths and angles of interest 
were those around the copper(II) centre, i.e. Cu-N and Cu-O. These bond lengths were 
comparable with complexes within this study as well as those reported in literature. The same 
can be said for bond angles where all angles occur within a comparable range. Co-ligands 
without hydrogen bonding capabilities lead to geometries with perpendicular ligands. 
Hydrogen bonding lead to distortions in this geometry. The solid state interactions that these 
chelates are capable of, provide important information as to whether these systems will be 
effective DNA binders. 
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Chapter 6 | Computational Chemistry 
6.1 Introduction 
6.1.1 Fundamental Concepts of Molecular Simulations 
 
Computational chemistry (molecular simulations) is a powerful tool which provides valuable 
information on the molecular geometry of compounds. It uses quantum mechanics and 
mathematical formulations to solve and investigate chemically relevant problems using 
computational simulations. Chemists frequently utilise these tools to investigate various 
aspects and features of molecules including the chemical reactivity, characterisation spectra 
(IR, NMR and UV/Vis), molecular geometry, electronic structure and substrate‒enzyme 
interactions.81 
Various computational methods exist such as Molecular Mechanics, Ab Initio, Semi‐empirical 
calculations, Density Functional Theory (DFT) and Molecular dynamics. Density Functional 
Theory simulations have been used in this study to gain a deeper understanding of the 
experimental solid state structures. In particular, the influence of intermolecular interactions 
on the solid state structures determined in the crystallographic studies.82  
To simulate the properties of interest for a chemical compound an understanding of the 
electron configuration of the molecule is required. Since an electron’s position cannot be 
defined precisely, a wavefunction is utilised to calculate the electron distribution of a 
molecule. The wavefunction represents the probability of finding electrons in certain 
locations.83  Calculating wavefunctions of molecules is not possible for any molecule larger 
than a hydrogen atom, therefore DFT calculations (which are based on the Schrödinger 
equation) use an indirect method of finding an approximate solution to the wavefunction. The 
method uses the electron distribution of a molecule to determine the ground-state electronic 
configuration. The ground-state electronic configuration is then used to calculate the 
wavefunction, after which various properties of a molecule can be calculated i.e. DFT finds an 
approximate solution to the Schrodinger equation by making certain assumptions regarding 
electron density of a molecule.81, 82 
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DFT simulations require the application of both a functional and a basis set. A functional is an 
instruction which produces a number from a set of coordinates or variables. A functional is a 
mathematical entity related to a function which produces a number from a function (a 
function of a function). The basis set is a set of atomic functions which describes the number 
and type of atomic orbitals which are considered in the calculation of a particular molecule.81 
Basis sets are fundamentally the region of space to which each electron is restricted. The 
fewer the number of restrictions on the positions of each electron, the more accurate the 
prediction of the molecular orbitals. The drawback is that the more degrees of freedom that 
are allowed, the longer the simulations take to complete.81 
Of all modern functionals, B3LYP (which is a hybrid functional) has proven the most popular 
and is the functional of choice for this work.83 B3LYP takes into account both the electron spin 
densities and electron spin gradients and is therefore classified as a  
gradient-corrected functional. This functional was coupled with the 6-311G (d,p) basis set 
which is restricted to atoms from H to Kr. This split valence basis set incorporates the 
hyperpolarisabilities for the d and p orbitals which greatly improves the accuracy of the 
molecular simulations.81 The basis set 6-311G is restricted from H-Kr, but has been shown to 
give more accurate results than the broader basis set 3-21G, which could also be used in this 
study as it is applicable to atoms in the range H-Xe. The basis set 6-311G applies fewer 
restrictions to the electrons during the calculation and gives more accurate results, but 
requires greater computational time. Considering the relatively small size of the molecules of 
interest, the larger basis set could be applied while keeping simulations times acceptable. The 
6-311G basis set is therefore an appropriate basis set for the single-ligand as well as the 
heteroleptic copper(II) chelates of interest.  
 
6.1.2 Objectives 
The main objective of this work is to determine the influence of intermolecular interactions in 
the solid state on the geometry of the metal chelates. The calculations will provide insight into 
the chemistry of both the single-ligand and heteroleptic copper(II) chelates. The geometry-
optimised structures of the metal chelates in vacuo will be simulated. The vibrational 
frequency calculations will also be run as they are pivotal in determining whether the 
geometry optimisations are true global minima on the potential energy surface. 




The DFT simulations were run at the B3LYP/6-311G(d,p) level of theory 84, 85, 86, 87, 88, 89, 90 using 
GAUSSIAN09W.91 The X-ray structure coordinates were used, where possible, as the input 
structures for the full geometry optimisations. All simulations of the copper(II) chelates 
excluded counter ions and solvent molecules. No restrictions were imposed during the 
geometry optimisations. The frequency simulations showed no negative Eigen values 
suggesting that all the optimised structures are true minima on the global potential energy 
surface. All atom numbering within this chapter corresponds with that used in Chapter 5. 
 
6.2 Results and Discussion 
6.2.1 Geometry Optimisations of Single-ligand Copper(II) Chelates 
 
To fully understand the consequences of the methanol solvent molecule on the geometry of 
[Cu(L2)Cl2], the geometry of the structure (metal chelate only) was optimised in the gas phase 
and compared to the experimentally determined solvated and non-solvated structures. The 
experimental X-ray structure and simulated structure were compared using structural 
overlays (least squares fits) (Figure 6.2.1).  The similarity of the calculated and simulated 
structures suggests, as indicated by the relatively small root-mean-square deviations (RMSD), 
the level of theory used for the calculations was appropriate and the results are likely to be 
reliable. The bond parameters for the experimental and calculated structures are summarised 
in Table 6.2.1 and Figure 6.2.1, respectively. The gas-phase structure is 47.8 kJ mol-1 lower in 
energy than the solid-state desolvated structure and 10.68 kJ mol-1 lower in energy than the 
solid state solvated structure. Surprisingly, the solvated chelate has a lower RMSD of 0.470 Å 
compared to the non-solvated chelate with an RMSD of 0.508 Å as well as a lower ΔE value. 
These data suggest that the structure has to undergo minimal deformation from the true 
lowest energy conformation to allow for optimum hydrogen bonding with the methanol 
solvate molecule. This small required deviation from the lowest energy conformation coupled 
with the energy gained through hydrogen bonding would suggests that the solvated structure 
is significantly more stable than the desolvated structure. 
















Figure 6.2.1: Comparison of DFT-calculated (purple) and X-ray crystal structures (green), (a) the desolvated structure of 
[Cu(L2)(Cl)2], (b) the methanol monosolavted X-ray structure of Cu(L2)Cl2] and (c) the monomer of the  
µ-chloro bridged structure of [Cu(L1)Cl]. Root mean square deviations (RMSDs) for all non-hydrogen atoms 
for each structure are indicated on the diagram (Å) along with ΔE (kJ mol-1). ΔE represents the energy 
difference between the solid-state and gas phase structures. 
 
Table 6.2.1: Comparison of experimental and DFT-calculated bond lengths (Å) and angles (°) for [Cu(L2)(Cl)2] and 
[Cu(L2)(Cl)2]·MeOH. 
Bond lengths (Å) 
   Experimental Calculated Difference* (%) Difference* (%) 
 [Cu(L2)(Cl)2] [Cu(L2)(Cl)2]·MeOH  [Cu(L2)(Cl)2] [Cu(L2)(Cl)2]·MeOH 
N1-Cu1 1.985(1) 1.989(2) 2.1133 6.07 5.88 
N3-Cu1 2.046(2) 2.034(2) 1.9199 -6.57 -5.94 
N2-Cu1 2.042(1) 2.027(2) 1.9125 -6.77 -5.99 
Cl1-Cu1 2.4616(5) 2.5208(6) 2.2060 -11.59 -1.82 
Cl2-Cu1 2.2567(6) 2.2461(5) 2.2061 -2.29 -14.26 
C=Nimine 1.282(2) 1.289(2) 1.2754 -0.52 -1.07 
(a) 
RMSD = 0.507 Å 
ΔE = 47.8 kJ mol-1 
 
(b) 
RMSD = 0.470 Å 
ΔE = 10.86 kJ mol-1 
 
(c) 
RMSD = 0.335 Å 
ΔE = 31.2 kJ mol-1 
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Table 6.2.1 continued… 
*Percentage Difference = 
(𝐶𝑎𝑙𝑐−𝐸𝑥𝑝)
𝐶𝑎𝑙𝑐
 𝑥 100 
 
The data in Table 6.2.1 show that the majority of the bond lengths and angles of the optimised 
and experimental structures compare favourably. The greatest difference in the bond angles 
is for angle Cl1-Cu1-Cl2. The DFT-calculated angle is 153.33° while the experimental data 
shows more acute angles measuring 105.26(2)° and 108.45(2)° for the solvated and  
non-solvated chelates, respectively. This is likely a result of the chloride ions being involved in 
hydrogen bonding with the methanol solvent molecule in the crystal lattice. Another key 
difference lies in the angles at which the two chloride ions are positioned relative to the rest 
of the complex. In the experimental structures Cl1 is approximately perpendicular to the 
complex while Cl2 is nominally co-planar with the basal plane of the complex. It would seem 
that the additional stability gained through the hydrogen bonding in the solid state is sufficient 
to offset the energy required for this deviation from the true lowest energy structure in the 
gas phase. Additionally, in the absence of packing constraints in the lattice, the chloro ligands 
can adopt a more obtuse angle which would alleviate any non-bonded repulsion between the 
ligands. 
With respect to the bond distances, it is noted that the experimental N1-Cu1 bond length is 
shorter than the DFT-simulated distance. The distances between the metal centre and N2 and 
N3 are larger than the simulated length of 1.9199 Å. It is also interesting to note that distance 
to N3 is slightly longer than N2. The bond between C=Nimine is a double bond and is longer than 
the simulated distance. The Cu-Cl bond distances are significantly different in the 
experimental structures with one Cu-Cl bond being significantly longer than the other in both 
complexes. This is not seen in the simulated structure where both Cu-Cl bond lengths are very 
similar. All other distances lie compare favourably with the DFT calculated distances.  
Bond angles (o) 
 Experimental Calculated Difference* (%) Difference* (%) 
 [Cu(L2)(Cl)2] [Cu(L2)(Cl)2]·MeOH  [Cu(L2)(Cl)2] [Cu(L2)(Cl)2]·MeOH 
N1-Cu1-N2 80.62(6) 80.62(6) 81.98 1.66 1.66 
N1-Cu1-N3 79.27(6) 79.62(6) 81.15 2.32 1.89 
N1-Cu1-Cl1 97.42(5) 96.76(5) 103.34 5.73 6.37 
Cl1-Cu1-Cl2 105.26(2) 108.45(2) 153.33 31.35 29.27 
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The solid state structure of [Cu(L1)Cl] is a dimer type structure which is bridged by two chloro 
ligands. Figure 6.2.1 (c) shows the experimental and DFT-optimised monomer of the chelate. 
The gas-phase structure is 31.2 kJ mol-1 lower in energy than the solid-state structure. The 
RMSD of 0.335 Å is relatively large for a small molecule showing that in the solid state the 
molecule has to undergo a relatively large deviation from the lowest energy conformation. 
Seemingly this energy difference is offset by the more favourable packing of the higher energy 
conformation. Figure 6.2.2 illustrates the least-squares fit of the experimental and the DFT-
simulated structures of the µ-chloro bridged structure with an RMSD of 0.763 Å for all non-
hydrogen atoms. The gas-phase structure is 68.9 kJ mol-1 lower in energy than the solid-state 
structure. The least-squares fit of the dimer structure illustrates a significant difference 
between the experimental and solid state structures as illustrated by the large RMSD. In the 
absence of packing constraints in vacuo, the ligands are able to adopt the lowest energy 
conformation. In the solid state the structure has to deviate from this true low energy 









Figure 6.2.2:  Least-squares fit of the experimental (green) and DFT-simulated (purple) dimeric structure of [Cu(L1)Cl]. 
[Left] Molecular overlay of the entire structure. [Right] An overlay of the quinoline and salicylideneimine 
moiety only. 
 
The structural overlay for [Cu(L1)Cl] (an overlay of the quinoline and salicylideneimine  moiety 
only) shows a RMSD of 0.215 Å which is lower than the corresponding molecule overlay. The 
lower RMSD confirms that the quinoline and salicylideneimine region of the calculated 
structure has been accurately simulated when compared to the experimental structure. The 
angle subtended by the bridged chloro ligands is responsible for the large variation in the 
RMSD = 0.763 Å 
 
RMSD = 0.215 Å 
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experimental and calculated structures. Table 6.2.2 provides a comparison of bond lengths 
and bond angles for [Cu(L1)(Cl)]. 














   
                         Percentage Difference = 
(𝐶𝑎𝑙𝑐−𝐸𝑥𝑝)
𝐶𝑎𝑙𝑐
 𝑥 100 
The most noticeable difference in the bond lengths is noted for the Cu1-Cl1* with Cl1* being 
the axial chloro ligand. The largest percentage difference with the experimental and calculated 
bond angles occurs with the angles associated with the chloride atoms. The experimental 
angle Cl1-Cu1-Cl1* measures 95.60(3)° which is significantly larger than the calculated angle 
which measures 90.86°. With the exception of the bond parameters involving the chloro 
ligands, the similarity of the selected bond lengths and bond angles for the experimental and 
geometry-optimised structures suggests that the chosen level of theory was appropriate.  
No crystal structure was obtained for [Cu(L)(Cl)2], therefore DFT simulations are important to 
determine the geometry of the chelate. The geometry of the chelate was optimised as a gas-
phase model. No negative Eigen values were obtained, thus the chelate has been optimised 
to the energy minimum on the global potential energy surface. The geometry-optimised 
structures for the copper(II) chelate is shown in Figure 6.2.3. 
Bond lengths (Å) 
 Experimental Calculated  Difference (%) 
Cu1-N1 1.973(3) 1.9900 0.85 
Cu1-N2 2.002(3) 2.0082 0.31 
Cu1-O1 1.908(3) 1.9322 1.25 
Cu1-Cl1 2.2924(9) 2.3251 1.41 
Cu1-Cl1* 2.8151(8) 2.6023 -8.18 
C10-N1 1.305(5) 1.3053 0.02 
Bond angles (o) 
 Experimental Calculated Difference (%) 
N1-Cu1-N2 82.3(1) 82.05 -0.30 
N1-Cu1-O1 93.7(1) 90.87 -3.11 
N2-Cu1-Cl1* 95.21 93.87 -1.43 
O1-Cu1-Cl1 89.09 90.38 1.43 
Cl1-Cu1-Cl1* 95.60(3) 90.86 -5.22 
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A summary of the calculated bond lengths and bond angles defining the coordination sphere 
of the copper(II) chelate are given in Table 6.2.3. Figure 6.2.3 is a partially labelled diagram 
showing the distorted square pyramidal geometry within the coordination sphere of the 







Figure 6.2.3: Partially labelled DFT-optimised structure showing the distorted square pyramidal geometry of [Cu(L)(Cl)2]. 
 









The structure of [Cu(L)(Cl)2] shows an interesting geometry around the copper(II) centre when 
compared to its closely related counterpart [Cu(L2)(Cl)2]. The basal plane of [Cu(L2)(Cl)2] 
comprises atoms N1, N2, N3 and Cl2, with Cl1 being the apical atom in the square pyramidal 
geometry. Correspondingly, the Cu1-Cl1 bond length is longer than that of Cu1-Cl2.  
Figure 6.2.3 shows that the basal plane of [Cu(L)(Cl)2] consists of N1, N3, Cl1 and Cl2, with the 
apical atom being N2. Similarly, the Cu1-N2 bond which measures 2.420 Å, is significantly 
larger than the corresponding bond lengths of Cu1-N1 (1.909 Å) and Cu1-N3 (1.981 Å). The 
additional flexibility afforded by the sp3 hybridised methylene bridging atom of [Cu(L)Cl] 
compared to the rigid aromatic nature of [Cu(L2)Cl] has allowed for this significantly different 
geometry. 
  Bond lengths (Å) Bond angles (°) 
N1-Cu1 1.909 N1-Cu1-N2 80.31 
N3-Cu1 1.981 N1-Cu1-N3 75.47 
N2-Cu1 2.420 N1-Cu1-Cl1 153.05 
Cl1-Cu1 2.181 Cl1-Cu1-Cl2 92.59 
Cl2-Cu1 2.141   
C=Nimine 1.278   
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6.2.2 Geometry Optimisation of the Heteroleptic Copper(II) Chelates 
Geometry optimisations and frequency calculations were performed on all copper(II) chelates 
using the level of theory described above. The absence of negative Eigen values suggests that 
the geometry optimised structures were true minima on the global potential energy surface. 
The least-squares fits of the three heteroleptic complexes are shown in Figure 6.2.4. The 
RMSDs for all non-hydrogen atoms indicate that the experimental and calculated structures 




















Figure 6.2.4:  Comparison of DFT-calculated (purple) and X-ray crystal structures (green) of structures (a) [Cu(L1)(Bpy)](Cl), 
(b) [Cu(L1)(Phen)](Cl) and (c) [Cu(L1)(Phen-NH2)](Cl). RMSDs for all non-hydrogen atoms for each structure 





RMSD = 0.372 Å 
ΔE = 42.9 kJ mol-1 
 
(b) 
RMSD = 0.307 Å 
ΔE = 35.4 kJ mol-1 
 
(c) 
RMSD = 0.365 Å 
ΔE = 30.0 kJ mol-1 
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The RMSDs for the heteroleptic complexes are in most cases smaller than those of the single-
ligand complexes. The bidentate ligands have fewer degrees of freedom and allow for fewer 
conformational distortions. Hence there is greater similarity between the experimental and 
calculated structures.  
The RMSD for [Cu(L1)(Bpy)](Cl) measures 0.372 Å with the gas-phase structure being  
42.9 kJ mol-1 lower in energy than the solid-state structure. The similarity of the calculated 
and experimental structures suggests the level of theory used for the calculations was 
appropriate and the simulations are likely to be reliable.  The structural overlay for 
[Cu(L1)(Bpy)](Cl) (an overlay of the quinoline and salicylideneimine moiety only) shows an 
RMSD of 0.133 Å and is depicted in Figure 6.2.5. This shows a similar trend to that observed 
previously: the most significant difference between the structures lies in the angle between 








Figure 6.2.5:  Structural overlay of the experimental (green) and DFT-simulated (purple) for the quinoline and 
salicylideneimine moiety only of [Cu(L1)(Bpy)](Cl). 
 
A summary of key calculated and experimental bond lengths and bond angles is given in  
Table 6.2.5 along with the percentage difference between these data. 
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Percentage Difference = 
(𝐶𝑎𝑙𝑐−𝐸𝑥𝑝)
𝐶𝑎𝑙𝑐
 𝑥 100 
From Table 6.2.4 it can be concluded that all bond lengths are in good agreement as indicated 
by the small percentage differences. From the structural overlay in Figure 6.2.5 it is evident 
that the quinoline and salicylideneimine region of the calculated structure has been accurately 
simulated when compared to the experimental structure. The key difference lies in the angle 
N1-Cu1-N4 which shows a very large deviation between the gas-phase and solid state 
structures. The angle is larger for the gas-phase structure by 13.39°; this significantly changes 
the overall geometry of the chelate. In the gas phase, the copper(II) chelate is not restricted 
by lattice packing and so the geometry optimisation yields a chelate structure with the lowest 
steric strain and correspondingly the lowest energy.  
 
 
Bond lengths (Å) 
 Experimental Calculated Difference (%) 
Cu1-N1 2.214(4) 2.295 3.53 
Cu1-N2 2.017(3) 2.076 2.84 
Cu1-N3 2.022(3) 2.030 0.39 
Cu1-N4  1.954(3) 1.973 0.96 
Cu1-O1 1.931(2) 1.911 -1.05 
C=Nimine 1.311(5) 1.314 0.23 
Bond angles (o) 
 Experimental Calculated Difference (%) 
N1-Cu1-N2 78.1(1) 75.64 -3.25 
N4-Cu1-O1 93.3(1) 93.12 -0.19 
N3-Cu1-N4 82.6(1) 82.57 -0.04 
N1-Cu1-N4 97.80(1) 111.49 12.28 
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The RMSD for [Cu(L1)(Phen)](Cl) measures 0.307 Å with the gas-phase structure being  
35.4 kJ mol-1 lower in energy than the solid-state structure (Figure 6.2.4). The structural 
overlay for [Cu(L1)(Phen)](Cl) (an overlay of the quinoline and salicylideneimine moiety only) 








Figure 6.2.6:  Structural overlay of the experimental (green) and DFT-simulated (purple) of the quinoline and 
salicylideneimine moiety only for [Cu(L1)(Phen)](Cl). 
Figure 6.2.6 shows a similar result to that previously discussed where the quinoline and 
salicylideneimine regions are in good agreement with each other in the gas phase and the 
solid state structures. The most significant deviations are observed in the angle between the 
co-ligand and primary ligand. The relevant bond lengths and bond angles for [Cu(L1)(Phen)](Cl) 
are summarised in Table 6.2.5 and Table 6.2.6. The consequence of this small deviation, 
however, is a significantly different molecular geometry. 
 








Bond lengths (Å) 
 Experimental Calculated Difference (%) 
Cu1-N1 1.962(3) 1.972 0.51 
Cu1-N2 2.014(3) 2.031 0.84 
Cu1-N3 2.293(3) 2.331 1.63 
Cu1-N4  2.034(3) 2.071 1.79 
Cu1-O1 1.911(3) 1.909 -0.10 
C=Nimine 1.287(4) 1.313 1.98 
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         Percentage Difference = 
(𝐶𝑎𝑙𝑐−𝐸𝑥𝑝)
𝐶𝑎𝑙𝑐
 𝑥 100 
All bond angles and bond lengths around the coordination sphere lie within good agreement 
of each other in the gas-phase and solid state structures. This is confirmed by the small 
percentage differences which range from 0.10 – 1.98 %. The exception is the N1-Cu1-N3 bond 
angle which measures 96.74(1)° in the solid state while the in vacuo structure shows a 
corresponding angle of 109.49°. The reason for the deviation in the bond angle is likely that 
the solid state structure has to deviate from the lowest energy structure to allow for optimal 
packing in the lattice. 
The most interesting of the three structures is [Cu(L1)(Phen-NH2)](Cl) since this is the only 
heteroleptic compound with the potential to hydrogen bond. This is significant as hydrogen 
bonding has been previously shown to lead to marked deviations between the lowest energy 
structures and those observed experimentally.51 The RMSD for [Cu(L1)(Phen-NH2)](Cl) 
measures 0.365 Å with the gas-phase structure being 30.0 kJ mol-1 lower in energy than the 
solid-state structure. The structural overlay for [Cu(L1)(Phen-NH2)](Cl) (an overlay of the 







Bond angles (o) 
 Experimental Calculated Difference (%) 
N1-Cu1-N2 83.05(1) 82.57 -0.58 
N1-Cu1-O1 93.42(1) 93.15 -0.29 
N3-Cu1-N4 77.52(1) 76.62 -1.17 
N1-Cu1-N3 96.74(1) 109.49 11.64 








Figure 6.2.7: Structural overlay of the experimental (green) and DFT-simulated (purple) of the quinoline and 
salicylideneimine moiety only for [Cu(L1)(Phen-NH2)](Cl). 
As was observed with the previous two heteroleptic chelates, the quinoline and 
salicylideneimine moieties have a low RMSD value indicating that the geometry optimisation 
results are reliable. From the crystallographic studies, it was observed that the NH2 group was 
involved in hydrogen bonding with the chloride counter ion as well as the oxygen atom of the 
Schiff base ligand.  The molecule has seemingly had to undergo minimal deviation from the 
lowest energy conformation to allow for optimum hydrogen bonding. This is an unusual result 
and suggests that the hydrogen bonding groups are coincidentally pre-organised for optimum 
hydrogen bonding. This is an encouraging result as it shows that the complex will likely be able 
to hydrogen bond with the DNA helix with minimal distortion, stabilising the DNA/drug 
conjugate. Key bond lengths and bond angles are summarised in Table 6.2.7. 




Bond lengths (Å) 
 Experimental Calculated Difference (%) 
Cu1-N1 1.957(2) 1.974 0.86 
Cu1-N2 2.010(1) 2.032 1.08 
Cu1-N3 2.013(2) 2.061 2.33 
Cu1-N4  2.241(2) 2.333 3.94 
Cu1-O1 1.940 (9) 1.912 -1.46 
C=Nimine 1.305(2) 1.314 0.68 
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Table 6.2.7 continued… 
     Percentage Difference = (𝐶𝑎𝑙𝑐−𝐸𝑥𝑝)
𝐶𝑎𝑙𝑐
 𝑥 100 
 
Table 6.2.7 shows a summary of the bond angles and lengths defining the coordination sphere 
of the copper(II) ion. The calculated bond lengths are all similar, as expected, with Cu1-N4 
being slightly longer in the gas phase. Once again, the bond angle of interest, N1-Cu1-N4, is 
larger in the gas phase than in the solid state structure. This angle deviation is ubiquitous in 
all six structures studied. This is an interesting result as it shows that the simulated structures 
are tending towards a trigonal bipyramidal structure as opposed to the square pyramidal 
structure observed in the solid state. These geometries are both well known for copper(II) 
chelates, however, trigonal bipyramidal structures tend to be lower in energy as there is 
reduced steric strain in the complexes. It therefore stands to reason that in the gas phase, in 
the absence of packing constraints, the molecules are tending as far as possible towards a 
trigonal bipyramidal geometry. 
 
6.3 Conclusions 
The geometry optimisations for all copper(II) chelates were performed at the  
B3LYP/6-311G(d,p) level of theory. A good correlation was observed between the gas phase 
and solid state structures for all the chelates. DFT simulations were used to determine to the 
structure of [Cu(L)(Cl)2] which proved to be difficult to crystallise. 
Similar trends emerged for all the copper(II) chelates studied; both the single-ligand and 
heteroleptic chelates. The geometry of the tridentate ligands coordinated to the copper(II) ion 
was consistently in good agreement with the experimental data. The main difference between 
the experimental (solid state) and simulated (gas phase) structures lies in the angle subtended 
by the co-ligands. In all cases this angle was more obtuse in the gas phase models showing the 
Bond angles (o) 
 Experimental Calculated Difference (%) 
N1-Cu1-N2 82.95(6) 82.51 -0.53 
N1-Cu1-O1 92.89(6) 93.04 0.16 
N3-Cu1-N4 78.78(6) 76.56 -2.90 
N1-Cu1-N4 100.15(6) 109.05 8.16 
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lowest energy conformations were tending towards a trigonal bipyramidal geometry. 
Seemingly more favourable packing of the square pyramidal structures in the solid state was 
enough to offset the energy difference between the lowest energy conformations and those 
observed experimentally. The hydrogen bonding of [Cu(L1)(Phen-NH2)]Cl did not (surprisingly) 
lead to any significant structural distortions in the solid state. 
Overall, it can be concluded that the B3LYP/6-311G(d,p) level of theory which was used for 
the DFT simulations was appropriate and the data simulated for the gas phase structures was 
reliable and in good agreement with the solid state structures. 
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Chapter 7 | Biological studies 
7.1 Introduction 
The square pyramidal copper(II) chelates synthesised in this work have been designed to act 
as chemotherapeutic agents, exerting their cytotoxicity through DNA binding (intercalation 
and/or groove binding) interrupting DNA replication. This will in turn lead to cell apoptosis. 
The cytotoxic effects will be further enhanced by the ability of the copper(II) metal centre to 
catalyse hydroxyl radical production. Previous discussion highlighted the various chemical 
properties of the copper(II) chelates which make them suitable for the development of 
chemotherapeutic agents including their ctDNA binding affinities  and ability to produce ROS. 
In the development of potential chemotherapeutic agents, it is vital to investigate the 
cytotoxicity by screening the chelates against a wide range of cancer cell lines. The copper(II) 
chelates presented in this work was screened in vitro against a panel of four human cell lines 
by the Advanced Materials Division at MINTEK in South Africa. The cell screening will not only 
show how effectively the metal chelates control the proliferation of tumour cells, but will also 
show any preference the copper chelates may have towards particular cell lines. This 
specificity is key as preferential cytotoxicity towards specific cell lines will reduce the side-
effects associated with chemotherapy. 
In this study, the chelates were screened against a panel of three human cancer cell lines and 
one normal human cell line. The IC50 values for each chelate were measured. The cell lines of 
choice represent some of the most prevalent forms of cancer and also form a representative 
cross-section of the more than 200 forms of cancer. Screening against a normal human cell 
line was carried out to investigate the cytotoxic effects on normal healthy tissue. The cell lines 
are: 
 
1. Human embryo kidney cells (Normal)  HEK293 
2. Human histiocytic lymphoma   U937  
3. Human renal carcinoma     TK-10 
4. Human leukaemia T cells    MT-4  
Daunorubicin is a commercially available anticancer agent which acts as a DNA intercalator 
and topoisomerase II poison. The dose response curve of a central nervous system cancer cell 
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line with the chemotherapeutic agent Daunorubicin is illustrated in Figure 7.1.1. The growth 
percentage is the growth of the inoculated tumour cell line relative to a control batch. It is 

















The cytotoxicity of a drug can be measured via three dose response parameters, each being 
the concentration of a drug required to reduce cell proliferation to a specified extent. These 
dose parameters are: 
 GI50 value: concentration of the compound where there is 50% growth inhibition 
compared to the control. This is a 50% reduction in the nett protein increase in control 
cells during the drug incubation. 
 IC50 value: concentration of the compound at which there is total growth inhibition. 
There is no net increase in the quantity of protein at the end of the experiment. 
 LC50 value: concentration of the compound resulting in a 50% reduction in the 
measured protein at the end of drug treatment compared with the beginning. This 
indicates a net loss of cells following treatment.92 
 
 






























Figure 7.1.1: Dose‐response curve of a central nervous system cancer cell line with the chemotherapeutic. 
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A great deal of research has been carried out where the cytotoxic effects of several copper 
chelates were screened against various human cancer cell lines. A study by Lu et. al. screened 
two closely related copper(II) chelates to those of this study against lung adenocarcinoma 












The -log IC50 values for [Cu(L)Cl](ClO4) and [Cu(L)Br2] as well as that of cisplatin against A549 
are summarised in Table 7.1.1. The –log IC50 values indicate that the two copper(II) chelates 
have great potential to act as anticancer agents having a higher activity than cisplatin; the 
current industry standard for metallodrugs. 
 
Table 7.1.1: -log IC50 values (µM) of similar copper(II) chelates and cisplatin against cancer cell line A549.2 





A study by Fernandes et. al. investigated the cytotoxicity of a range of novel copper(II) chelates 
against two human leukemia cell lines, acute monocytic leukemia (THP-1) and histiocytic 




Figure 7.1.2: Closely related copper(II) chelates (a) [Cu(L)Cl](ClO4) and (b) [Cu(L)Br2] which exhibit cytotoxic 
effects against the cancer cell line A549.2 








The study revealed that the copper(II) chelate, [(H2L2)Cu(μ-Cl)2Cu(H2L2)]Cl2 was the most 
cytotoxic of the chelates in the study. Comparative studies were also carried out with cisplatin 
on the two cell lines, THP-1 and U937. The copper chelate exerted a potent inhibitory effect 
on the growth of THP-1 and U937 cell lines. The -log IC50 values were reported to be 4.95 µM 
(THP-1) and 5.09 µM (U937). This is an improvement over cisplatin for cell line U937 (4.79 µM) 
and a comparable activity against THP-1 (4.92 µM). 
These selected data highlight the potential of copper(II) chelates as chemotherapeutic agents. 
In addition to the cell lines mentioned above, copper(II) compounds similarly have promising 
chemotherapeutic effects over a wide range of human cancer cell lines. As copper is an 
endogenous metal it is also possible that this enhanced activity towards tumour cells will be 










Figure 7.1.3:  Solid state structure of [(H2L2)Cu(μ-Cl)2Cu(H2L2)]Cl2. A potential copper(II)-based  
chemotherapeutic agent. 
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7.2 Experimental  
The cytotoxic effect of the copper(II) compounds were evaluated in four human cell lines  
(TK-10, HEK293, U937 and MT-4). The assay endpoint was determined via the Cell Titer 
Aqueous Non-Radioactive assay.94, 95 A 96 well microtiter plate was seeded with cells at a low 
passage number, at a concentration of 2 × 105 cells mL-1  in a total volume of 100 µL complete 
medium. The media contained 10% foetal bovine serum (FBS, Highveld Biological, R.S.A) and 
necessary antibiotics. After an incubation of 24 hours at 37 °C and 5% CO2, the test compounds 
were added in two-fold serial dilutions for a total of 8 concentrations  
(100 - 0.78 µM). After an incubation of 96 hours, 10 µL of the Cell Titer solution was added to 
each well; the contents were gently mixed and the plates incubated under the previously 
described conditions. The plates were read at time intervals of 2 and 4 hours at an absorbance 
wavelength of 490 nm on a microplate reader (xMarkTM, Bio-Rad). IC50 values were 
determined as the concentration of the test substance required to reduce cell viability by 50% 
using OriginPro® version 8.0 software (OriginLab Corporation, Northampton, MA, USA). The 
cell screening experiments were performed at Mintek (South Africa). 
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7.3 Results and Discussion 
7.3.1 Cytotoxic Activity of the Copper(II) Chelates 
The IC50 values measured for the six synthesised copper(II) chelates against a representative 
panel of four human cell lines (three neoplastic and one healthy) are reported in Table 7.3.1. 
 Table 7.3.1: The IC50 values (µM) of the copper(II) chelates against three human cancer cell lines and one healthy human 
cell line. 

















[Cu(L)(Cl)2] 3.18  - 3.22 1.16 2.19 ± 1.45 
[Cu(L1)(Cl)] 5.66  20.00 24.64 11.28 18.64 ± 6.78 
[Cu(L2)(Cl)2] 3.43  - 5.06 1.30 3.18 ± 2.66 
[Cu(L1)(Bpy)](Cl) 6.95  8.62 5.67 4.73 6.34 ± 2.03 
[Cu(L1)(Phen)](Cl) 11.08 3.65 11.18 4.18 6.33 ± 4.20 
[Cu(L1)(Phen-NH2)](Cl) 4.65 3.95 17.02 4.00 8.32 ± 7.53 
 
In General, compounds with lower IC50 values are more cytotoxic against the cancer cell lines. 
This data is counterintuitive, thus –log IC50 values are calculated. The lower the IC50 value of 
the copper(II) chelates, the larger its –log IC50 value. This allows for a clearer graphical 
representation of the data. Figure 7.3.1 shows a bar graph of the –logIC50 values of the metal 
chelates. 
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Figure 7.3.1: The -log IC50 values for the copper(II) chelates against four cell lines and their mean cytotoxicity. 
   
The data in Figure 7.3.1 illustrates that each compound has a unique cytotoxicity profile (i.e. 
each cell line responds differently to the drug candidate) and confirms that the compounds 
are genuine chemotherapeutics with a well-defined mechanism of action.  
HEK293 is a normal human cell line and was used a control in this study. The cytotoxic activity 
of the copper chelates towards the normal healthy cells illustrates the need for targeted drug 
delivery. The copper(II) chelates are similarly toxic to both healthy and tumour cells. By 
incorporating biomarkers (such as biotin) into the drug design it will ensure a higher uptake 
of the drug in neoplastic over healthy tissue. An interesting point highlighted by the data in is 
that [Cu(L2)Cl2] shows a significantly reduced cytotoxicity towards the healthy cell line while 
showing good toxicity towards tumour cell lines. This suggests that it may be a more suitable 
primary ligand for the development of the next generation of heteroleptic complexes. The 
reason for the reduced cytotoxicity is not clear, though it may be related to the reduced 
aromaticity and associated reduction in DNA binding affinity. 
The copper chelates all show the greatest cytotoxicity towards the leukaemia cell line MT-4. 
This suggests that the compounds could be most suitable for the treatment of this particular 
class of cancer. It would therefore be pertinent to test the compounds against a wider variety 
of leukaemia cell lines in future work. It is noteworthy that [Cu(L1)(Cl)] is the least cytotoxic of 
all the chelates. The addition of a co-ligand is required to increase the cytotoxicity. If the same 
trend holds for the other single-ligand chelates then the addition of co-ligands to [Cu(L)Cl2] 
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activity when compared to [Cu(L1)(Phen)](Cl). This is likely due to the NH2 group’s hydrogen 
bonding capabilities which stabilises the DNA/Drug conjugate. 
As previously discussed, the copper(II) chelates were designed to bind DNA as a key step to 
inhibit cell replication. A comparison of the DNA binding affinities and cytotoxicities is 
therefore relevant. Table 7.3.2 shows (rather unexpectedly) little relationship between DNA 
binding affinity and cytotoxicity. In the case of [Cu(L)(Cl)2], this chelate exhibits the highest 
cytotoxicity of the screened copper chelates, however, it possesses one of the lowest DNA 
binding affinities. Chelate [Cu(L1)(Cl)] possessed the lowest cytotoxicity, but had the highest 
DNA binding affinity. This shows that the mechanism of action is more complex than DNA 
binding alone. The redox activity of the copper(II) ion is therefore likely to be a key component 
in the cytotoxicity. Ligands which are more flexible, such as in complex [Cu(L)Cl2], may allow 
for the geometric changes required for a transition from copper(II) to copper(I) since each of 
these metal ions have different preferences for coordination geometry. 
Table 7.3.2: Relationship between the cytotoxicity and competitive EB-DNA binding affinities of the copper(II) chelates. 
Most effective                                                                                                                                                  Least effective 
Cytotoxicity: in vitro cell screening 
[Cu(L)(Cl)2] [Cu(L2)(Cl)2] [Cu(L1)(Bpy)](Cl) [Cu(L1)(Phen-NH2)](Cl) [Cu(L1)(Phen)](Cl) [Cu(L1)(Cl)] 
EB-ctDNA competitive binding affinities 
[Cu(L1)(Cl)] [Cu(L1)(Phen)(Cl)] [Cu(L1)(Phen-NH2)(Cl)] [Cu(L1)(Bpy)(Cl)] [Cu(L)(Cl2)] [Cu(L2)(Cl2)] 
 
The data in Figure 7.3.1 and Table 7.3.1 shows that the cytotoxicity of the metal chelates varies 
significantly. The cytotoxicity of each chelate also varies against each cell line. The lack of 
correlation between the cytotoxicity profile and the DNA binding affinities suggests that the 
mechanism of action of the chelates is more complicated than anticipated. The single-ligand 
copper(II) chelates are also more cytotoxic than the heteroleptic copper(II) chelates. The 
opposite is observed with the DNA binding studies which showed the heteroleptic chelates 
exhibited stronger binding affinities compared to the single-ligand chelates. A stated above 
the heteroleptic chelates may more effectively stabilise the metal ion, reducing the 
production of ROS and ultimately reducing the cytotoxicity. 
Another interesting trend is noted in both the cytotoxicity and DNA binding affinities of the 
single-ligand copper(II) chelates. [Cu(L)(Cl)2] and [Cu(L2)(Cl)2] both contained N,N’,N’’ donor 
sets. Both these chelates were the most active in the cell screening but were the weakest DNA 
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binders. [Cu(L1)(Cl)] contained N,N’,O donor atoms and displayed contrasting results. 
[Cu(L1)(Cl)] was the least active in the cell screening, but had the highest DNA binding affinity. 
[Cu(L2)(Cl)2] and [Cu(L1)(Cl)] are structurally comparable with the only difference between the 
two chelates being the donor atoms to the copper(II) metal centre. This observation suggests 
that the choice of donor atoms on the primary ligand system is significant and may have an 
impact on the cytotoxicity and DNA binding affinities.  
The –log IC50 values of the copper(II)  chelates for cell lines TK-10 and U937 as well as those of 
cisplatin, carboplatin and bleomycin (as acquired from the National Cancer Institute database 
and Su et. a.l.)96 are summarised in Table 7.3.3. Figure 7.3.2 illustrates the cytotoxicity profile 
of the copper(II) chelates with three commercially available chemotherapeutic agents. 
 Table 7.3.3: The -log IC50 values of the copper(II) chelates as well as cisplatin, carboplatin and bleomycin.5 
Compound TK-10 U937 
[Cu(L1)(Cl)] 4.70 ± 2.37 4.61 ± 5.56 
[Cu(L1)(Bpy)](Cl) 5.06 ± 2.39 5.25 ± 0.14 
[Cu(L1)(Phen)](Cl) 5.44 ± 0.92 4.95 ± 2.41 
[Cu(L1)(Phen-NH2)](Cl) 5.41 ± 0.54 4.77 ± 1.46 
Cisplatin 4.91  5.70 
Carboplatin 3.60   5.26 
Bleomycin 4.88   - 
 
Cisplatin and its analogue carboplatin are commonly used as industry standards against which 
anticancer agents are compared due to its high anticancer activity.97 Bleomycins are large 
water soluble glycoproteins which are derived from the bacteria Streptomyces verticillus. 
Bleomycins are known to chelate metal ions, which enhances their cytotoxicity towards 
cancerous cells.98 
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Figure 7.3.2: Comparison of the cytotoxicity of the copper(II) chelates with cisplatin, carboplatin and bleomycin. 
From the graph in Figure 7.3.2 it can be concluded that the copper chelates are more active 
against the TK-10 cell line when compared to the commercially available agents. The three 
heteroleptic copper(II) chelates showed higher activity than cisplatin and bleomycin, while the 
single-ligand copper(II) chelate were less active. Carboplatin is the least active of all the 
compounds listed. These data show that in terms of cytotoxicity the copper(II) chelates 
synthesised in this work have potential as chemotherapeutics.  
 
7.4 Conclusions 
Both the single-ligand and heteroleptic copper(II) chelates were screened against a panel of 
four human cell lines: HEK293, TK-10, U937 and MT-4. Of the four cell lines, one was a normal 
human cell line which was used as control (HEK293). From the graph in Figure 7.3.1, the most 
active chelate was found to be [Cu(L)(Cl)2] with the highest mean activity (-log IC50 = 5.60 µM) 
across all cancer cell lines. This chelate also showed the lowest toxicity towards the healthy 
cell line. [Cu(L2)(Cl)2] which is comparable in structure to [Cu(L)(Cl)2] exhibited the second 
highest mean activity (-log IC50 = 5.49 µM). 
The copper(II) chelates showed cytotoxicity against all four cell lines including the control cell 
line of normal cells. This highlights the importance of selective drug delivery to ensure that 
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the DNA binding affinity and cytotoxicity. This suggests a more complex mechanism of action 
and that the redox activity and the production of ROS in vitro is a key step in the induction of 
cell apoptosis. 
The chelates all showed enhanced activity against the TK-10 cell line, even having higher 
activity than cisplatin, carboplatin and bleomycin. The potential of the copper(II) chelates for 
the treatment of other leukaemia cell lines therefore warrants further testing.  
These data confirm that each compound has a unique cytotoxicity profile and can be regarded 
as genuine chemotherapeutics with a well-defined mechanism of action and are not merely 
poisons. The cytotoxicity of the copper(II) compounds compare well with previously reported 
copper(II) chelates.  
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Chapter 8 | Conclusions and Future Work 
8.1 Conclusions 
A range of copper(II) Schiff base single-ligand and heteroleptic chelates for potential use as 
chemotherapeutic agents were successfully synthesised and characterised (Figure 8.1.1). The 
metal serves two functions: firstly, acting as a scaffold around which DNA-targeting ligands 
can be arranged. Secondly, the biologically accessible redox potential of the metal can catalyse 










Figure 8.1.1: Structures of the copper(II) Schiff base complexes successfully synthesised in this work.  
The N,N’,N’’ and N,N’,O donor Schiff base ligands were synthesised in a one-step, one-pot 
reaction involving the condensation between the respective aldehydes and amines in a 1:1 
ratio. The ligands were characterized by 1H and 13C NMR experiments. In the case of the single-
ligand chelates, the metal complexes were synthesised by reacting the respective Schiff base 
ligands with CuCl2 in a 1:1 molar ratio. The isolated green precipitate of [Cu(L1)(Cl)] was then 
further reacted with three co-ligands: Bpy, Phen and Phen-NH2 to afford the three 
heteroleptic complexes.  
IR, Uv/vis and NMR spectroscopy, mass spectrometry and CHN analysis were employed to 
confirm the identity of the copper(II) chelates. Uv/vis spectroscopy illustrated that as the 
conjugation increases by the addition of a co-ligand the spectra gains a π → π* band between 
240 - 300 nm depending on the structure of the co-ligand. The MLCT band at approximately 
420 nm is ubiquitous in all spectra confirming the presence of the copper(II) metal centre. 
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The DNA binding affinity of the chelates was studied using fluorescence competitive binding 
DNA titrations and showed the influence of structural differences on the DNA binding 
affinities. The Kapp values of the six chelates range from 1.2(2) - 8.7(2) × 105 M-1 these compare 
favourably with the DNA binding affinity measured for the strong DNA intercalator ethidium 
bromide (7.75 × 105 M-1). [Cu(L1)(Cl)] showed the highest DNA binding with a Kapp value of 
8.65 × 105 M-1. The copper(II) chelates were also shown to produce hydroxyl radicals in the 
presence of hydrogen peroxide and ascorbate using a hydroxyl radical assay with Rhodamine 
B. This is significant as it is a key component in the mechanism of action of copper(II)-based 
drugs. 
The solid state structures of two single-ligand and three heteroleptic chelates were 
successfully elucidated using X-ray crystallography. Interestingly, [Cu(L2)(Cl2)] crystallized as 
two pseudopolymorphs where one lattice was solvated with a methanol molecule and the 
other was solvent-free. The copper(II) chelates all exhibited a square pyramidal coordination 
geometry around the metal centre which is in keeping with reported chelates of this class. The 
bond lengths and bond angles of the metal chelates were comparable to those reported in 
literature. Measurements of the angles between the ligand planes were taken and showed 
interesting variations of ring bending as well as angle deviations of the three heteroleptic 
complexes. The solid state interactions, particularly hydrogen bonding, of which these 
chelates are capable, provided important links between the solid-state structures and DNA 
binding affinities. 
The geometry optimisations for all copper(II) chelates were performed at the  
B3LYP/6-311G(d,p) level of theory. A good correlation was observed between the gas phase 
and solid state structures for all chelates. This was indicated by low RMSDs and indicates that 
the structures had to undergo minimal structural deformations to allow for optimum packing 
in the solid state. The B3LYP/6-311G(d,p) level of theory which was chosen for the DFT 
simulations was therefore appropriate and the data calculated for the gas phase structures 
was likely reliable. The main difference in all the structures was the angle subtended by the 
co-ligands; both the chloro ligands and the bidentate N-donor ligands. 
The copper(II) chelates were screened against a panel of four human cell lines: one normal 
cell line (HEK293) and three cancerous cell lines (TK-10, U937, MT-4). The HEK293 cell line was 
used as a control to investigate any specificity towards neoplastic tissue. The copper(II) 
chelates in general showed similar cytotoxicity in both the healthy and tumour cells. This data 
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therefore highlights the need for targeted drug delivery to ensure the chelates are selective 
towards cancerous tissue (vida infra). 
The most active chelate was found to be [Cu(L)(Cl)2] with the highest mean cytotoxicity  
(IC50 = 2.19 µM). Interestingly, the same chelate showed the lowest toxicity towards the 
healthy cell line HEK293 (IC50 = 3.18). This chelate could therefore be more suitable as the 
primary ligand for the development of the next generation of heteroleptic chelates. There was 
no correlation between DNA binding affinity and cytotoxicity. This suggests that the catalytic 
production of ROS in vitro, which are known to cleave DNA and induce apoptosis, is likely a 
key step in the mechanism of action. 
The proposed objectives of the project have been accomplished: DNA binding copper(II)-
based chemotherapeutics with good cytotoxicity have been successfully synthesised. The data 
obtained have shown a few interesting trends and will be an excellent grounding to many 
avenues of future research. 
8.2 Future work 
The research on the copper(II) chelates in this study shows there is significant potential for 
further development as chemotherapeutic agents. This preliminary data opens the floor to 
several possible areas of research which require further development. In the present work, 
two phenanthroline-derivatised co-ligands were also successfully synthesised and 
characterized by 1H and 13C NMR experiments: L3 and L4. These ligands contained a biotin and 
propionic acid substituent, respectively, appended to phenanthroline by an amide bond. 
Biotin was incorporated into the co-ligand design to aid with biodistribution of the chelates, 
making them more selective towards neoplastic tissue. Since many tumour cell lines  
over-express receptor sites for this important growth factor, appending it to the chelates 
should increase uptake in cancerous tissue.  The propionic acid derived ligand (L4) was 
synthesised as a control since both co-ligands contain the secondary amide functional group. 
Bioactivity studies, such as DNA binding and cell screening, will be undertaken on both to 
investigate the role biotin plays in terms of biodistribution and cell uptake. The proposed 
structures of chelates [Cu(L1)(L3)](Cl) and [Cu(L1)(L4)](Cl) are shown in Figure 8.2.1. 










Figure 8.2.1:  Structural formulae for chelates [Cu(L1)(L3)(Cl)] and [Cu(L1)(L4)(Cl)].  
Preliminary data for the synthesis of the above compounds is promising with the synthesis of 
both chelates confirmed using mass spectrometry. [Cu(L1)(L3)(Cl)] will be further discussed as 
a representative example for both chelates. The mass spectrum in Figure 8.2.2 shows a base 
peak of 731.2191 m/z which correlates to the molecular ion peak of [Cu(L1)(L3)(Cl)] (M+). The 
peak at 733.2188 m/z shows the expected isotopic ratio of Cu-63 and Cu-65 and is indicative 
of successful metal ion chelation. 
However, the spectrum also shows a number of unwanted materials. The two largest impurity 
peaks are 310.0352 m/z which correlates to [Cu(L1)(Cl)](M+), the primary ligand, while the 
peak 444.1732 m/z correlates to the biotin co-ligand’s mass. These peaks highlight that the 
reaction does not go to completion and further method development is still required.  
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Figure 8.2.2: Mass spectrum of [Cu(L1)(L3)(Cl)].  
 
In terms of co-ligand design and biodistribution, a study by Slim et al. successfully synthesised 
the biotin derivatized DPPZ ligand.99 The DPPZ-Biotin ligand along with its propionic acid 
derivative will also be synthesised as co-ligands in the future development of the heteroleptic 
complexes. Another study by Bos et al.100 showed the successful synthesis of a Bpy derivatized 
ligand which will be further reacted with biotin using methods previously described in this 
study for the synthesis of L3 and L4. Once again, the propionic acid derivative will also be 
synthesised for comparative studies. Figure 8.2.3 firstly shows a reaction scheme for the two 
desired ligands followed by the predicted chelate structures for the respective heteroleptic 
chelates. 
 
















Figure 8.2.3: Reaction schemes for the synthesis of co-ligands DPPZ-Biotin and Bpy-Biotin, as well as the structure of the 
desired copper(II) chelates.  
Another chelate modification will include changing the primary N,N’,O donor Schiff base ligand 
as was used in this research to an N,N’,N’’ donor Schiff base ligand. There are numerous 
possible N,N’,O and N,N’,N’’ donor Schiff base ligands, however, preference will be given to 
the Schiff bases which have already shown cytotoxic properties in the current study, i.e. ligand 
L from [Cu(L)(Cl)2]. 
In the early stages of drug design, the lipophilicity of the compounds has been shown to be a 
key physico-chemical property for determining biodistribution. The octonal-water partition 
coefficients will therefore be measured in the future work of this project. Lipophilicity gives 
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insight into the behaviour of the copper(II) chelates in the mammalian environment in terms 
of distribution, absorption, metabolism and excretion. It is also a reflection of the ability of a 
compound to permeate the cell membranes in a living organism.101 The intended cellular 
target of the copper(II) chelates is DNA. Therefore the efficiency with which the drugs can 
cross the phospholipid bilayer of cells is a key parameter in determining their success as 
chemotherapeutics. It has also been shown that any small changes to the structure of metal 
chelates can have a marked effect on cell uptake and biodistribution.  
DNA binding studies carried out in this work showed promising binding affinities as 
determined via competitive DNA binding studies. The exact mode through which the chelates 
bind to the DNA is, however, unknown. The method applied does not discriminate between 
intercalation and groove binding. Gel electrophoresis and DNA melting experiments will be 
carried out to investigate the exact DNA binding mode. In gel electrophoresis the mobility of 
the DNA through the agarose gel is largely dependent on the length of the DNA molecule. If 
the copper(II) chelate intercalates the DNA strand, the strand is lengthened resulting in 
reduced mobility.102 
Melting of DNA is a phenomenon observed when double-stranded DNA molecules are heated 
and separated into two single strands. This is caused by disruption of the intermolecular forces 
such as π-π stacking and hydrogen bonding interactions which stabilise the DNA helix. This is 
monitored by the resulting hyperchromic effect in the DNA absorption spectra. The melting 
temperature (Tm) is the temperature at which half of the total base pairs are un-bonded and 
is easily measured form a DNA melting curve. The presence of a molecule intercalated 
between the double-stranded DNA will result in a notable increase in the value of Tm. Results 
from DNA melting will provide insight into the binding mode of the copper(II) chelates.102 
The copper(II) chelates in this study have been tested against four human cell lines from 
MINTEK in order to determine a cross section of the cytotoxicity profile. An improved, more 
accurate representation of the cytotoxicity can be achieved by increasing the number of cell 
lines with the National Cancer Institute’s sixty human cell line panel (NCI 60). This will provide 
an activity profile for the chelates which can be compared with other compounds with known 
modes of action, giving an indication of the likely mechanism of action. These data will also be 
important as the preliminary data has shown increased cytotoxicity towards leukaemia cells. 
Testing the chelates against different forms of leukaemia will confirm a preference for the 
treatment of leukaemia.   
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Further studies that are still to be carried out on all existing and the proposed paramagnetic 
copper(II) chelates using Electron Spin Resonance (ESR) spectroscopy since NMR is not 
amenable to  the study of paramagnetic copper(II) chelates.  
Lastly, the copper(II) chelates will be radiolabelled using the isotope 64Cu. Radiolabelling the 
chelates will enable several experiments such as biodistribution determination, PET imaging 
applications and xenograft experiments. In biodistribution experiments, the radiolabelled 64Cu 
chelates are injected into Sprague Dawley rats. After a set period of time, the rats are 
sacrificed and the radioactivity of each organ is measured. This is an important test for 
copper(II)-based drugs as if the metal ion is not sufficiently stabilised toxic liver accumulation 
is observed. This would prevent their application as metallodrugs. 
The radiolabelled chelates will also be utilised in xenograft experiments. These experiments 
will determine whether the chelates are selective towards neoplastic vs healthy tissue as well 
as show whether the chelates can reduce the size of tumours in vivo. A ‘sack’ of cancerous 
cells is inserted into an animal followed by a dose of the chelate, which is administered 
intravenously. After a set amount of time the xenograft is removed and the growth of the cells 
measured. The selective tissue uptake of the chelate is also measured by the radioactivity of 
the xenograft. 
PET is an imaging technique in which a computer-generated image of a radioactive tracer 
distributed in tissue is produced through the detection of annihilation photons (refer to the 
introduction for a full explanation). These photons are emitted when radionuclides are 
introduced into the body, decay and release positrons. PET is a favourably sensitive, non-
invasive imaging technique that is well suited for pre-clinical and clinical imaging of cancerous 
regions in the body. The imaging of target molecules which are associated with cancer should 
allow for earlier diagnosis and better management of oncology patients. 
An eventual goal of this project is to develop “theranostic” agents, a compound in which a 
combination of diagnostic and therapeutic capabilities exist in a single agent. The addition of 
cell targeting groups as discussed above will be key to achieving this goal.  
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